ID,SEQUENCE,LENGTH,NOMENCLATURE,SOURCE,CELL LINE,INHIBITION/IC50,UNIT,TARGET,ASSAY,PMID,PAPER,AUTHORS,REFERENCE,,,,,,,,,,,,,,,,,,,,,
HIP144,AEAMSQVTN,9,-,gag,CEM/LAV-1,5,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP140,AAAMSQVTN,9,-,gag,CEM/LAV-1,100,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP142,AEAMAQVTN,9,-,gag,CEM/LAV-1,124,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP233,AEASQVTNTATIM,13,-,gag,CEM/LAV-1,126,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP266,AEAMSQVTNTATIM,14,-,gag,CEM/LAV-1,10,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP265,AEAMSQVANTATIM,14,-,gag,CEM/LAV-1,110,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP264,AEAASQVTNTATIM,14,-,gag,CEM/LAV-1,142,μM,Autolysis,PR inhibition assay,15113844,Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.,Misumi S, Morikawa Y, Tomonaga M, Ohkuma K, Takamune N, Shoji S.,J Biochem. 2004 Mar;135(3):447-53.,,,,,,,,,,,,,,,,
HIP184,KPKQIKPPLPSV,12,vif 155-166,Phage display,H9,100,%,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP195,SPYPSWSTPAGR,12,VMI16,Phage display,H9,High,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP196,SVSVGMKPSPRP,12,VMI5,Phage display,H9,High,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP193,SNQGGSPLPRSV,12,VMI7,Phage display,H9,High,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP186,LPLPAPSFHRTT,12,VMI9,Phage display,H9,High,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP192,SNFASITTPRPH,12,VMI1,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP220,YPLPHPMWSMLP,12,VMI10,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP213,TMTPPPTSVRGT,12,VMI11,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP214,TPLPTIRGDTGT,12,VMI12,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP180,GPPPHHRDYHGP,12,VMI13,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP219,YPAPIKVLLPNS,12,VMI14,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP194,SPYPMALFPLHN,12,VMI15,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP217,WPTNPTTVPVPS,12,VMI2,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP187,LTSDTYFLPVPA,12,VMI3,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP191,SLHWPVSHPPPP,12,VMI4,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP216,WHSQRLSPVPPA,12,VMI6,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP190,SEPHLPFPVLPH,12,VMI8,Phage display,H9,Medium,NA,Blocks multimerization of vif proteins,Affinity binding assay,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP287,ESAIRKAILGHIVSP,15,vif 117-131,Phage display,H9,10,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP360,SVTKLTEDRWNKPQK,15,vif 165-179,Phage display,H9,10,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP355,RWNKPQKTKGHRGSH,15,vif 173-187,Phage display,H9,10,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP351,RHHYESTHPRISSEV,15,vif 41-55,Phage display,H9,10,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP289,ESTHPRISSEVHIPL,15,vif 45-59,Phage display,H9,12,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP325,LGQGVSIEWRKKRYS,15,vif 81-95,Phage display,H9,12,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP279,DCFSESAIRKAILGH,15,vif 113-127,Phage display,H9,14,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP354,RKAILGHIVSPRCEY,15,vif 121-135,Phage display,H9,15,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP301,HTGERDWHLGQGVSI,15,vif 73-87,Phage display,H9,15,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP328,LTEDRWNKPQKTKGH,15,vif 169-183,Phage display,H9,25,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP348,RDWHLGQGVSIEWRK,15,vif 77-91,Phage display,H9,25,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP356,RYSTQVDPDLADQLI,15,vif 93-107,Phage display,H9,25,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP273,AGHNKVGSLQYLALA,15,vif 137-151,Phage display,H9,30,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP280,DLADQLIHLYYFDCF,15,vif 101-115,Phage display,H9,34,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP372,VSPRCEYQAGHNKVG,15,vif 129-143,Phage display,H9,35,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP346,QVDPDLADQLIHLYY,15,vif 97-111,Phage display,H9,35,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP375,WQVMIVWQVDRMRIR,15,vif 5-19,Phage display,H9,42,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP277,CEYQAGHNKVGSLQY,15,vif 133-147,Phage display,H9,45,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP321,KVGSLQYLALAALIT,15,vif 141-155,Phage display,H9,45,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP338,PPLPSVTKLTEDRWN,15,vif 161-175,Phage display,H9,45,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP275,ALAALITPKKIKPPL,15,vif 149-163,Phage display,H9,64,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP327,LQYLALAALITPKKI,15,vif 145-159,Phage display,H9,65,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP342,QLIHLYYFDCFSESA,15,vif 105-119,Phage display,H9,68,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP326,LITPKKIKPPLPSVT,15,vif 153-167,Phage display,H9,85,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP320,KKIKPPLPSVTKLTE,15,vif 157-171,Phage display,H9,85,%,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP329,LYYFDCFSESAIRKA,15,vif 109-123,Phage display,H9,Low,NA,Blocks multimerization of vif proteins,ELISA,12480936,Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.,Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H.,J Biol Chem. 2003 Feb 21;278(8):6596-602. Epub 2002 Dec 11.,,,,,,,,,,,,,
HIP1170,IYWNVSGW,8,11,Synthetic,293T,7,μM,Budding,Reverse two-hybrid system,19053244,Inhibition of HIV budding by a genetically selected cyclic peptide targeting the Gag-TSG101 interaction.,Tavassoli A, Lu Q, Gam J, Pan H, Benkovic SJ, Cohen SN.,ACS Chem Biol. 2008 Dec 19;3(12):757-64.,,,,,,,,,,,,,,,,
HIP1019,CYHCQ,5,10,Tat,MT-4,63,%,Fusion inhibitor,MTT assay,12504126,Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.,Lohr M, Kibler KV, Zachary I, Jeang KT, Selwood DL,Biochem Biophys Res Commun. 2003 Jan 10;300(2):609-13.,,,,,,,,,,,,,,,,,
HIP1064,ASTTTNYT,8,peptide T,Synthetic,NA,High,NA,Fusion inhibitor,Immunoprecipitation,3026840,CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide.,Ruff MR, Martin BM, Ginns EI, Farrar WL, Pert CB.,FEBS Lett. 1987 Jan 19;211(1):17-22.,,,,,,,,,,,,,,,,,
HIP1021,KKCCYHCQ,8,6,Tat,MT-4,45,%,Fusion inhibitor,MTT assay,12504126,Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.,Lohr M, Kibler KV, Zachary I, Jeang KT, Selwood DL,Biochem Biophys Res Commun. 2003 Jan 10;300(2):609-13.,,,,,,,,,,,,,,,,,
HIP147,WMEWDREI,9,PBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP146,WASLWNWF,9,TRD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1020,YCKKCCYHCQ,10,5,Tat,MT-4,50,%,Fusion inhibitor,MTT assay,12504126,Small HIV-1-Tat peptides inhibit HIV replication in cultured T-cells.,Lohr M, Kibler KV, Zachary I, Jeang KT, Selwood DL,Biochem Biophys Res Commun. 2003 Jan 10;300(2):609-13.,,,,,,,,,,,,,,,,,
HIP215,TYICEVEDQKEE,12,CD4 (81-92),V1J1 region of the CD4 molecule,CEM-SS,>500,μM,Fusion inhibitor,Cytopathic effect,2078014,Peptides derived from the CDR3-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus-induced cell fusion, and postinfection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents.,Rausch DM, Hwang KM, Padgett M, Voltz AH, Rivas A, Engleman E, Gaston I, McGrath M, Fraser B, Kalyanaraman VS, et al.,Ann N Y Acad Sci. 1990;616:125-48. Review.,,,,,,,,,
HIP1162,RINNIPWSEAMM,12,12p1,Phage display,Cf2Th,1.6,μM,Fusion inhibitor,ELISA,14967033,Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.,Biorn AC, Cocklin S, Madani N, Si Z, Ivanovic T, Samanen J, Van Ryk DI, Pantophlet R, Burton DR, Freire E, Sodroski J, Chaiken IM.,Biochemistry. 2004 Feb 24;43(7):1928-38.,,,,,,,,,,
HIP1090,AAAQWDFGNTMC,12,PL1,CCR5,NIH-3T4,High,NA,Fusion inhibitor,Reporter gene assay,14576050,Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.,Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G.,Blood. 2004 Feb 15;103(4):1211-7. Epub 2003 Oct 23.,,,,,,,,,,,,,,,,,,
HIP1081,LFFLLTVPFWAHYA,14,LC2,CCR5,MT-4,Low,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP1149,CSSHFPYSQYQFWK,14,2C,CCR5,TZM-bl,28,μM,Fusion inhibitor,Neutralization Assay,22403408,Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.,Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.,J Biol Chem. 2012 Apr 27;287(18):15076-86. Epub 2012 Mar 8.,,,,,,,,,,,,,
HIP315,KGACDYPEWQWLCAA,15,PIE7,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1082,LKARTVTFGVVTSVI,15,LC3,CCR5,MT-4,Low,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP1085,FFIILLTIDRYLAVV,15,LC6,CCR5,MT-4,Low,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP1127,IRKAHCNISRADWND,15,15D,gp120,CEMx174,50,nM,Fusion inhibitor,QPCR,21264298,Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture.,Chertov O, Zhang N, Chen X, Oppenheim JJ, Lubkowski J, McGrath C, Sowder RC 2nd, Crise BJ, Malyguine A, Kutzler MA, Steele AD, Henderson EE, Rogers TJ.,PLoS One. 2011 Jan 11;6(1):e14474.,,,,,,,,,
HIP1126,IRKAHCNISRAKWND,15,15K,gp120,CEMx174,50,nM,Fusion inhibitor,QPCR,21264298,Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture.,Chertov O, Zhang N, Chen X, Oppenheim JJ, Lubkowski J, McGrath C, Sowder RC 2nd, Crise BJ, Malyguine A, Kutzler MA, Steele AD, Henderson EE, Rogers TJ.,PLoS One. 2011 Jan 11;6(1):e14474.,,,,,,,,,
HIP1100,GIGDPVTCLKSGAIA,15,15GIG,gp120,CEMx174,Low,NA,Fusion inhibitor,QPCR,21264298,Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture.,Chertov O, Zhang N, Chen X, Oppenheim JJ, Lubkowski J, McGrath C, Sowder RC 2nd, Crise BJ, Malyguine A, Kutzler MA, Steele AD, Henderson EE, Rogers TJ.,PLoS One. 2011 Jan 11;6(1):e14474.,,,,,,,,,
HIP1167,TRQARRNRRRWRERQR,16,Rev 34-50,rev,MT-2,1.7,μM,Fusion inhibitor,MAGI assay,20580677,Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.,Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. Epub 2010 May 16.,,,,,,,,,,,
HIP384,SLEQIWNNMTWMQWDK,16,CBD1,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1092,QEFFGLNNCSSSNRLD,16,PL3,CCR5,NIH-3T6,High,NA,Fusion inhibitor,Reporter gene assay,14576050,Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.,Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G.,Blood. 2004 Feb 15;103(4):1211-7. Epub 2003 Oct 23.,,,,,,,,,,,,,,,,,,
HIP406,KGACELLGWEWAWLCAA,17,D10-p5-2K,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP473,KKGACEARHREWAWLCAA,18,D10-p1-2K,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1094,NCCAPEDIGFCLEGGCLV,18,P7,GBV-C E1,3T3,High,NA,Fusion inhibitor,Hemolysis assays,21905195,Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.,Sanchez Martin MJ, Urban P, Pujol M, Haro I, Alsina MA, Busquets MA.,Chemphyschem. 2011 Oct 24;12(15):2816-22. doi: 10.1002/cphc.201100407. Epub 2011 Sep 8.,,,,,,,,,,,,,,,,
HIP1095,APEDIGFCLEGGCLVALG,18,P8,GBV-C E1,3T3,High,NA,Fusion inhibitor,Hemolysis assays,21905195,Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.,Sanchez Martin MJ, Urban P, Pujol M, Haro I, Alsina MA, Busquets MA.,Chemphyschem. 2011 Oct 24;12(15):2816-22. doi: 10.1002/cphc.201100407. Epub 2011 Sep 8.,,,,,,,,,,,,,,,,
HIP1096,FCLEGGCLVALGCTICTD,18,P10,GBV-C E1,3T3,Low,NA,Fusion inhibitor,Hemolysis assays,21905195,Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.,Sanchez Martin MJ, Urban P, Pujol M, Haro I, Alsina MA, Busquets MA.,Chemphyschem. 2011 Oct 24;12(15):2816-22. doi: 10.1002/cphc.201100407. Epub 2011 Sep 8.,,,,,,,,,,,,,,,,
HIP1097,QAGLAVRPGKSAAQLVGE,18,P18,GBV-C E1,3T3,Medium,NA,Fusion inhibitor,Hemolysis assays,21905195,Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.,Sanchez Martin MJ, Urban P, Pujol M, Haro I, Alsina MA, Busquets MA.,Chemphyschem. 2011 Oct 24;12(15):2816-22. doi: 10.1002/cphc.201100407. Epub 2011 Sep 8.,,,,,,,,,,,,,,,,
HIP1098,AQLVGELGSLYGPLSVSA,18,P22,GBV-C E1,3T3,Medium,NA,Fusion inhibitor,Hemolysis assays,21905195,Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.,Sanchez Martin MJ, Urban P, Pujol M, Haro I, Alsina MA, Busquets MA.,Chemphyschem. 2011 Oct 24;12(15):2816-22. doi: 10.1002/cphc.201100407. Epub 2011 Sep 8.,,,,,,,,,,,,,,,,
HIP1080,INVKQIAARLLPPLYSLV,18,LC1,CCR5,MT-4,Low,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP1083,VFASLPGIIFTRSQKEGL,18,LC4,CCR5,MT-4,Low,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP1086,APERASSVYTRSTGEQEI,18,LC7,CCR5,MT-4,Low,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP457,GSASCTIAALGSSDRDTV,18,P41,GBV-C E2,CEM-174,10,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP503,PAIEPPTGTFGFFPGVPP,18,P82,GBV-C E2,CEM-174,10,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP483,LNNCLLLGTEVSEALGGA,18,P88,GBV-C E2,CEM-174,10,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP420,CPTPAIEPPTGTFGFFPG,18,P81,GBV-C E2,CEM-174,15,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP486,LQEVDAGNFIPPPRWLLL,18,P109,GBV-C E2,CEM-174,20,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP416,CLLLGTEVSEALGGAGLT,18,P89,GBV-C E2,CEM-174,25,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP545,YEPLVRRRSELMGRRNPV,18,P96,GBV-C E2,CEM-174,25,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP476,LGTEVSEALGGAGLTGGF,18,P90,GBV-C E2,CEM-174,28,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP515,QGHLQEVDAGNFIPPPRW,18,P108,GBV-C E2,CEM-174,30,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP455,GRPDGFIHVQGHLQEVDA,18,P105,GBV-C E2,CEM-174,35,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP436,EVSEALGGAGLTGGFYEP,18,P91,GBV-C E2,CEM-174,35,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP427,DGFIHVQGHLQEVDAGNF,18,P106,GBV-C E2,CEM-174,40,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP440,FHRCGAGPKLTKDLEAVP,18,P60,GBV-C E2,CEM-174,40,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP468,IHVQGHLQEVDAGNFIPP,18,P107,GBV-C E2,CEM-174,45,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP534,TGEKVWDRGNVTLLCDCP,18,P11,GBV-C E2,CEM-174,45,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP525,SDRDTVVELSEWGVPCAT,18,P45,GBV-C E2,CEM-174,50,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP490,LVRRRSELMGRRNPVCPG,18,P97,GBV-C E2,CEM-174,55,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP432,DTVVELSEWGVPCATCIL,18,P46,GBV-C E2,CEM-174,60,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP516,RFPFHRCGAGPKLTKDLE,18,P59,GBV-C E2,CEM-174,60,%,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP543,WVNQLAVLGLPAVDAAVA,18,P124,GBV-C E2,CEM-174,Low,332.7,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP540,VPVGSASCTIAALGSSDR,18,P40,GBV-C E2,CEM-174,Low,NA,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP489,LVKCPTPAIEPPTGTFGF,18,P80,GBV-C E2,CEM-174,Low,NA,Fusion inhibitor,Gp41-Mediated Cell-Cell Fusion Assay,20718496,Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.,Herrera E, Tenckhoff S, Gomara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.,J Med Chem. 2010 Aug 26;53(16):6054-63.,,,,,,,,,,,,
HIP511,PLNNCLLLGTEVSEALGG,18,P10,GBV-C E2,NA,14,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP484,LNNCLLLGTEVSEALGGA,18,P9,GBV-C E2,NA,23,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP498,NNCLLLGTEVSEALGGAG,18,P8,GBV-C E2,NA,25,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP495,NCLLLGTEVSEALGGAGL,18,P7,GBV-C E2,NA,27,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP417,CLLLGTEVSEALGGAGLT,18,P6,GBV-C E2,NA,28,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP481,LLLGTEVSEALGGAGLTG,18,P5,GBV-C E2,NA,32,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP479,LLGTEVSEALGGAGLTGG,18,P4,GBV-C E2,NA,37,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP477,LGTEVSEALGGAGLTGGF,18,P3,GBV-C E2,NA,44,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP533,TEVSEALGGAGLTGGFYE,18,P1,GBV-C E2,NA,54,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP462,GTEVSEALGGAGLTGGFY,18,P2,GBV-C E2,NA,60,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP1166,RFPFHRCGAGPKLTKDLE,18,P59,GB virus C,NA,530,μM,Fusion inhibitor,Fluorescence titration,21377446,Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.,Haro I, Gomara MJ, Galatola R, Domenech O, Prat J, Girona V, Busquets MA,Biochim Biophys Acta. 2011 Jun;1808(6):1567-73. Epub 2011 Mar 4.,,,,,,,,,,,,,,,
HIP1084,LRCRNEKKRHRAVRLIFTI,19,LC5,CCR5,MT-4,High,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP548,CLLLGTEVSEALGGAGLTG,19,P18,GBV-C E2,NA,18,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP554,LLLGTEVSEALGGAGLTGG,19,P11,GBV-C E2,NA,35,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP556,NNCLLLGTEVSEALGGAGL,19,P20,GBV-C E2,NA,36,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP555,NCLLLGTEVSEALGGAGLT,19,P19,GBV-C E2,NA,44,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP644,LEAIPCSIPPEFLFGKPFVF,20,VIR576,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP564,CLLLGTEVSEALGGAGLTGG,20,P12,GBV-C E2,NA,33,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP673,NNCLLLGTEVSEALGGAGLT,20,P21,GBV-C E2,NA,34,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP683,PLNNCLLLGTEVSEALGGAG,20,P22,GBV-C E2,NA,43,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP719,VPPLNNCLLLGTEVSEALGG,20,P23,GBV-C E2,NA,46,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP1150,QKEGLHYTCSSHFPYSQYQF,20,3,CCR5,TZM-bl,237,μM,Fusion inhibitor,Neutralization Assay,22403408,Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.,Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.,J Biol Chem. 2012 Apr 27;287(18):15076-86. Epub 2012 Mar 8.,,,,,,,,,,,,,
HIP1036,QPSVQIQVYQGEREIAAHNK,20,p407-426,HSP70,PM-1,77.2,%,Fusion inhibitor,RT assay,17251296,Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426.,Babaahmady K, Oehlmann W, Singh M, Lehner T.,J Virol. 2007 Apr;81(7):3354-60. Epub 2007 Jan 24.,,,,,,,,,,,,,,,,,,
HIP735,GLLASLGKVFGGYLAEKLKPK,21,Dahlein 5.6,Litoria dahlii,T cells,20,%,Fusion inhibitor,GFP expression,16140737,Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.,J Virol. 2005 Sep;79(18):11598-606.,,,,,,,,
HIP1168,TRQARRNRRRWRERQRAAAAC,21,Rev 34-50 A4C,rev,MT-2,0.35,μM,Fusion inhibitor,MAGI assay,20580677,Rev-derived peptides inhibit HIV-1 replication by antagonism of Rev and a co-receptor, CXCR4.,Shimane K, Kodama EN, Nakase I, Futaki S, Sakurai Y, Sakagami Y, Li X, Hattori T, Sarafianos SG, Matsuoka M.,Int J Biochem Cell Biol. 2010 Sep;42(9):1482-8. Epub 2010 May 16.,,,,,,,,,,,
HIP738,LEAIPMSIPPEVKFNKPFVF,21,VIRIP,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1063,KKKMVLGVFALLSLISGSLKK,21,Tar1,gp41,TZM-bl,High,NA,Fusion inhibitor,Luciferase assay,22413880,HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion.,Reuven EM, Dadon Y, Viard M, Manukovsky N, Blumenthal R, Shai Y.,Biochemistry. 2012 Apr 3;51(13):2867-78. Epub 2012 Mar 23.,,,,,,,,,,,,,,,,
HIP739,NCLLLGTEVSEALGGAGLTGG,21,P13,GBV-C E2,NA,34,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP744,NNCLLLGTEVSEALGGAGLTGG,22,P14,GBV-C E2,NA,30,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP956,APKEWMAWAREIAAYAKLIAALI,23,Ncap MT,gp41,HeLa,1.7,μM,Fusion inhibitor,Syncytia assay,11118065,Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.,Jin BS, Ryu JR, Ahn K, Yu YG.,AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1797-804.,,,,,,,,,,,,,,,,,,
HIP747,LNNCLLLGTEVSEALGGAGLTGG,23,P15,GBV-C E2,NA,38,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP1125,AVGIGAMFLGFLGAAGSTMGAAS,23,-,gp41,TZM-bl,23,nM,Fusion inhibitor,Luciferase assay,22520838,Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.,Anastassopoulou CG, Ketas TJ, Sanders RW, Johan Klasse P, Moore JP.,Virology. 2012 Jul 5;428(2):86-97. Epub 2012 Apr 19.,,,,,,,,,,,,,,,,,
HIP754,PLNNCLLLGTEVSEALGGAGLTGG,24,P16,GBV-C E2,NA,28,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP1148,RSQKEGLHYTCSSHFPYSQYQFWK,24,1,CCR5,TZM-bl,136,μM,Fusion inhibitor,Neutralization Assay,22403408,Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.,Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.,J Biol Chem. 2012 Apr 27;287(18):15076-86. Epub 2012 Mar 8.,,,,,,,,,,,,,
HIP1091,RSQKEGLHYTCSSHFPYSQYQFWK,24,PL2,CCR5,NIH-3T5,High,NA,Fusion inhibitor,Reporter gene assay,14576050,Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.,Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G.,Blood. 2004 Feb 15;103(4):1211-7. Epub 2003 Oct 23.,,,,,,,,,,,,,,,,,,
HIP759,PPLNNCLLLGTEVSEALGGAGLTGG,25,P17,GBV-C E2,NA,26,%,Fusion inhibitor,ANTS/DPX Assay,19402654,Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.,Herrera E, Gomara MJ, Mazzini S, Ragg E, Haro I.,J Phys Chem B. 2009 May 21;113(20):7383-91.,,,,,,,,,,,,,,,,,
HIP1089,MDYQVSSPIYDINYYTSEPCQKINVK,26,PNt,CCR5,NIH-3T3,Low,NA,Fusion inhibitor,Reporter gene assay,14576050,Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5.,Agrawal L, VanHorn-Ali Z, Berger EA, Alkhatib G.,Blood. 2004 Feb 15;103(4):1211-7. Epub 2003 Oct 23.,,,,,,,,,,,,,,,,,,
HIP1129,RQLLSGIVQQQNNLLRAIEAQQHLLQK,27,N27,gp41,TZM-bl,338,nM,Fusion inhibitor,Luciferase assay,20605950,Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.,Wexler-Cohen Y, Ashkenazi A, Viard M, Blumenthal R, Shai Y.,FASEB J. 2010 Nov;24(11):4196-202. Epub 2010 Jul 6.,,,,,,,,,,,,,,,,,
HIP957,APKEWMAWAREIAAYAKLIAALIKQGI,27,Caps MT,gp41,HeLa,1,μM,Fusion inhibitor,Syncytia assay,11118065,Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.,Jin BS, Ryu JR, Ahn K, Yu YG.,AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1797-804.,,,,,,,,,,,,,,,,,,
HIP955,APKEWMEWDREINNYTSLIHSLIKQGI,27,Caps WT,gp41,HeLa,5.8,μM,Fusion inhibitor,Syncytia assay,11118065,Design of a peptide inhibitor that blocks the cell fusion mediated by glycoprotein 41 of human immunodeficiency virus type 1.,Jin BS, Ryu JR, Ahn K, Yu YG.,AIDS Res Hum Retroviruses. 2000 Nov 20;16(17):1797-804.,,,,,,,,,,,,,,,,,,
HIP760,GLMDTVKNVAKNLAGHMLDKLKCKITGC,28,Ranatuerin-2P ,Rana pipiens,T cells,35,%,Fusion inhibitor,GFP expression,16140737,Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.,J Virol. 2005 Sep;79(18):11598-606.,,,,,,,,
HIP769,WMEWDREINNYTSLIHSLIEESQNQQEK,28,C28,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP766,RQLLSQIVQQQNNLLRAIEAQQHLLQLT,28,T36,gp41,CEM,45,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP768,VWGIKQLQARILAVERYLKDQQLLGIWG,28,T5,gp41,CEM,55,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP763,MTLTVQARQLLSQIVQQQNNLLRAIEAQ,28,T37,gp41,CEM,75,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP764,QARQLLSQIVQQQNNLLRAIEAQQHLLQ,28,T48,gp41,CEM,83,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP762,INNYTSLIHSLIEESQNQQEKNEQELLE,28,T623,gp41,CEM,3598,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP761,INNYTSLIGSLIEESQNQQEKNEQELLE,28,T51,gp41,CEM,100000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP767,VQQQNNLLRAIEAQQHLLQLTVWGIKQL,28,T33,gp41,CEM,>100,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP765,QHLLQLTVWGIKQLQARILAVERYLKDQ,28,T35,gp41,CEM,>100,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP774,NNYTSLIHSLIEESQNQQEKNEQELLELDK,30,HBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP772,EWDREINNYTSLIHSLIEESQNQQEKNEQE,30,SJ-2176,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1164,YGGIKKEIEAIKKEQEAIKKKIEAIEKEIEA,31,Izm,gp41,293T,0.026,μM,Fusion inhibitor,Luciferase assay,11572974,Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,Eckert DM, Kim PS.,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,,,,,,,,,,,,,,,,,,,,
HIP775,QIWNNMTWMEWDREINNYTSLIHSLIEESQNQ,32,CP32,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1062,AVGIGALFLGFLGAAGSTMGARSAMTLTVQRQL,33,FP,gp41,TZM-bl,High,NA,Fusion inhibitor,Luciferase assay,22413880,HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion.,Reuven EM, Dadon Y, Viard M, Manukovsky N, Blumenthal R, Shai Y.,Biochemistry. 2012 Apr 3;51(13):2867-78. Epub 2012 Mar 23.,,,,,,,,,,,,,,,,
HIP1073,AEGIGALFLGFLGAAGSTMGARSMTLTVQARQL,33,V2E,gp41,TF228,High,NA,Fusion inhibitor,Fluorescence assay,9153194,Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study.,Kliger Y, Aharoni A, Rapaport D, Jones P, Blumenthal R, Shai Y.,J Biol Chem. 1997 May 23;272(21):13496-505.,,,,,,,,,,,,,,,,
HIP1072,AVGIGALFLGFLGAAGSTMGARSMTLTVQARQL,33,WT,gp41,TF228,High,NA,Fusion inhibitor,Fluorescence assay,9153194,Fusion peptides derived from the HIV type 1 glycoprotein 41 associate within phospholipid membranes and inhibit cell-cell Fusion. Structure-function study.,Kliger Y, Aharoni A, Rapaport D, Jones P, Blumenthal R, Shai Y.,J Biol Chem. 1997 May 23;272(21):13496-505.,,,,,,,,,,,,,,,,
HIP1117,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,C34,gp41,TZM-bl,16.83,nM,Fusion inhibitor,Pseudovirus assay,22760295,A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.,Zhao L, Tong P, Chen YX, Hu ZW, Wang K, Zhang YN, Zhao DS, Cai LF, Liu KL, Zhao YF, Li YM.,Org Biomol Chem. 2012 Aug 28;10(32):6512-20. Epub 2012 Jul 4.,,,,,,,,,
HIP778,ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ,34,Dermaseptin,Phyllomedusa sauvagii,T cells,45,%,Fusion inhibitor,GFP expression,16140737,Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.,J Virol. 2005 Sep;79(18):11598-606.,,,,,,,,
HIP788,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,C34,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP781,VEWNEMT WMEWEREI ENYTKLIYKILEESQEQ,34,CP32M,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP780,SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQAR,34,N34,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP779,SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQCCGR,34,N34ccg,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1123,WEEWDRKIEEYTKKIKKLIEESQEQQEKNEKELK,34,SC34,gp41,NA,0.39,nM,Fusion inhibitor,MAGI Assay,12203417,Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.,Otaka A, Nakamura M, Nameki D, Kodama E, Uchiyama S, Nakamura S, Nakano H, Tamamura H, Kobayashi Y, Matsuoka M, Fujii N.,Angew Chem Int Ed Engl. 2002 Aug 16;41(16):2937-40. No abstract available.,,,,,,,,,,,
HIP1124,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,C34,gp41,NA,0.68,nM,Fusion inhibitor,MAGI Assay,12203417,Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.,Otaka A, Nakamura M, Nameki D, Kodama E, Uchiyama S, Nakamura S, Nakano H, Tamamura H, Kobayashi Y, Matsuoka M, Fujii N.,Angew Chem Int Ed Engl. 2002 Aug 16;41(16):2937-40. No abstract available.,,,,,,,,,,,
HIP1103,WMEWEREIDNYTSEIYTLIEESQNQQEKNEQELL,34,C34,gp41,TZM-bl,High,NA,Fusion inhibitor,Fluorescence anisotropy,19763181,Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.,Miyauchi K, Kozlov MM, Melikyan GB.,PLoS Pathog. 2009 Sep;5(9):e1000585. Epub 2009 Sep 18.,,,,,,,,,,,,,,,,,,,
HIP1093,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,C34,gp41,MT-2,High,NA,Fusion inhibitor,Immunoprecipitation,12805467,Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.,Kilgore NR, Salzwedel K, Reddick M, Allaway GP, Wild CT.,J Virol. 2003 Jul;77(13):7669-72.,,,,,,,,,,,,,,,,,
HIP786,WMEWDREINNYTSLIHSLIEEWQNQQEKNEQELL,34,C34S138W,C34,HeLa,> 1000 (>137),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP783,WMEWDREINNYTSLIHSLIEELQNQQEKNEQELL,34,C34S138L,C34,HeLa,1.5±0.4(0.2),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP782,WMEWDREINNYTSLIHSLIEEAQNQQEKNEQELL,34,C34S138A,C34,HeLa,2.0±0.4(0.3),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP785,WMEWDREINNYTSLIHSLIEETQNQQEKNEQELL,34,C34S138T,C34,HeLa,2.6±0.2(0.4),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP784,WMEWDREINNYTSLIHSLIEEPQNQQEKNEQELL,34,C34S138P,C34,HeLa,46±11(6.3),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP787,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,C34,C34,HeLa,7.3±2.5,nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP1163,RMKQIEDKIEEIESKQKKIENEIARIKKLIGERY,34,GCN4-pIQI,gp41,293T,>25,μM,Fusion inhibitor,Luciferase assay,11572974,Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region.,Eckert DM, Kim PS.,Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11187-92.,,,,,,,,,,,,,,,,,,,,
HIP799,WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKK,35,C35-EK,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1173,IKKTYEEIKKTYEEIKKTYEEIKKTYEEIKKTYEE,35,5HR,Synthetic,H9/HIV-1I,>200,μM,Fusion inhibitor,ELISA,18662985,Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.,Qi Z, Shi W, Xue N, Pan C, Jing W, Liu K, Jiang S.,J Biol Chem. 2008 Oct 31;283(44):30376-84. Epub 2008 Jul 28.,,,,,,,,,,,,,,,
HIP802,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE,35,T624,gp41,CEM,2,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP801,WMEWDREINNYTSLIGSLIEESQNQQEKNEQELLE,35,T624,gp41,CEM,6,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP793,INNYTSLIHSLIEESQNQQEKNEQELLELDKWASL,35,T622,gp41,CEM,230,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP797,TWQEWERKVDFLEENITALLEEAQIQQEKNMYELQ,35,T390,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP803,WQEWERKVDFLEENITALLEEAQIQQEKNMYELQK,35,T391,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP795,QEWERKVDFLEENITALLEEAQIQQEKNMYELQKL,35,T392,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP791,EWERKVDFLEENITALLEEAQIQQEKNMYELQKLN,35,T393,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP800,WERKVDFLEENITALLEEAQIQQEKNMYELQKLNS,35,T394,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP790,ERKVDFLEENITALLEEAQIQQEKNMYELQKLNSW,35,T395,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP796,RKVDFLEENITALLEEAQIQQEKNMYELQKLNSWD,35,T396,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP794,KVDFLEENITALLEEAQIQQEKNMYELQKLNSWDV,35,T397,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP798,VDFLEENITALLEEAQIQQEKNMYELQKLNSWDVF,35,T398,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP789,DFLEENITALLEEAQIQQEKNMYELQKLNSWDVFG,35,T399,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP792,FLEENITALLEEAQIQQEKNMYELQKLNSWDVFGN,35,T400,gp41,CEM,High,NA,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP1151,SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,36,HXB2 546–581,gp41,293T,7,μM,Fusion inhibitor,Pseudovirus assay,22235115,Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.,Zhuang M, Wang W, De Feo CJ, Vassell R, Weiss CD.,J Biol Chem. 2012 Mar 9;287(11):8297-309. Epub 2012 Jan 10.,,,,,,,,,,,,,,,,
HIP1118,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T20 ,gp41,293T,222,nM,Fusion inhibitor,Pseudovirus assay,22235115,Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.,Zhuang M, Wang W, De Feo CJ, Vassell R, Weiss CD.,J Biol Chem. 2012 Mar 9;287(11):8297-309. Epub 2012 Jan 10.,,,,,,,,,,,,,,,,
HIP815,HSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW,36, T-20-A,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP807,EELAKKAEELAKKAEELAKKAEELAKKAWASLWNWF,36,4HRa-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP806,EEAAKKLEEAAKKLEEAAKKLEEAAKKLWASLWNWF,36,4HRb-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP805,EALAKAAEALAKAAEALAKAAEALAKAAWASLWNWF,36,4HRc-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP809,EEYTKKIEEYTKKIEEYTKKIEEYTKKIWASLWNWF,36,4HR-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP851,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,36,C36,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP837,SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,36,N36,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP849,WMEWDREIEEYTKKIEEYTKKIEEYTKKIEEYTKKI,36,PBD-4HR,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP848,WMEWDREIEEYTKKIEEYTKKIEEYTKKIEEYTKKI,36,PBD-4HRa,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP847,WMEWDREIEELAKKAEELAKKAEELAKKAEELAKKA,36,PBD-4HRb,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP846,WMEWDREIEEAAKKLEEAAKKLEEAAKKLEEAAKKL,36,PBD-4HRc,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP842,SWETWEREIENYTKQIYKILEESQEQQDRNEKDLLE,36,Sifuvirtide,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP877,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T-20,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1174,IKKTYEEIKKTYEEIKKTYEEIKKTYEEIERDWEMV,36,4HR-LBD,Synthetic,H9/HIV-1I,117,μM,Fusion inhibitor,ELISA,18662985,Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.,Qi Z, Shi W, Xue N, Pan C, Jing W, Liu K, Jiang S.,J Biol Chem. 2008 Oct 31;283(44):30376-84. Epub 2008 Jul 28.,,,,,,,,,,,,,,,
HIP873,YTSLIHSLIEESQNQQEKNEQELLELDKWASLFNFF,36,T379,gp41,CEM,0.3,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP869,YTSLIHSLIEESQNQQEKNEQELLEFDKWASLWNWF,36,T703,gp41,CEM,0.5,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP876,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T20,gp41,CEM,0.6,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP852,WNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQ,36,T654,gp41,CEM,1,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP872,YTSLIHSLIEESQNQQEKNEQELLELDKWASLANWF,36,T96,gp41,CEM,1,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP883,YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF,36,T97,gp41,CEM,2,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP886,YTSLIHSLIEESQQQQEKNEQELLELDKWASLWNWF,36,T212,gp41,CEM,3,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP867,YTSLIHSLIEESQNLQEKNEQELLELDKWASLWNWF,36,T701,gp41,CEM,3,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP895,YTSLIQSLIEESQNQQEKNEQQLLELDKWASLWNWF,36,T231,gp41,CEM,4,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP829,NMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL,36,T652,gp41,CEM,4,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP840,SLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI,36,T638,gp41,CEM,5,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP834,QIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKN,36,T656,gp41,CEM,5,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP884,YTSLIHSLIEESQNQQEKNEQQLLELDKWASLWNWF,36,T230,gp41,CEM,6,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP850,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,36,T649,gp41,CEM,8,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP882,YTSLIHSLIEESQNQQEKNEQELLQLDKWASLWNWF,36,T98,gp41,CEM,10,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP823,LIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIT,36,T637,gp41,CEM,12,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP880,YTSLIHSLIEESQNQQEKNEQELLELDKWASPWNWF,36,T705,gp41,CEM,14,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP833,NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW,36,T640,gp41,CEM,15,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP891,YTSLIHSLIEQSQNQQEKNEQELLELDKWASLWNWF,36,T214,gp41,CEM,19,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP843,TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN,36,T639,gp41,CEM,21,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP892,YTSLIHSLIQESQNQQEKNEQELLELDKWASLWNWF,36,T215,gp41,CEM,23,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP881,YTSLIHSLIEESQNQQEKNEQELLELNKWASLWNWF,36,T213,gp41,CEM,25,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP825,MEWDREINNYTSLIHSLIEESQNQQEKNEQELLELD,36,T648,gp41,CEM,36,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP868,YTSLIHSLIEESQNQQEKLEQELLELDKWASLWNWF,36,T702,gp41,CEM,36,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP874,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNAF,36,T95,gp41,CEM,43,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP813,EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDK,36,T647,gp41,CEM,44,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP844,TWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLE,36,T650,gp41,CEM,44,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP885,YTSLIHSLIEESQNQQEKNQQELLQLDKWASLWNWF,36,T99,gp41,CEM,56,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP830,NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQE,36,T653,gp41,CEM,63,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP875,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNSF,36,T706,gp41,CEM,68,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP845,WDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW,36,T646,gp41,CEM,83,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP804,DREINNYTSLIHSLIEESQNQQEKNEQELLELDKWA,36,T645,gp41,CEM,85,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP831,NNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWN,36,T641,gp41,CEM,98,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP817,IHSLIEESQNQQEKNEQELLELDKWASLWNWFNITN,36,T636,gp41,CEM,110,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP811,EQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQEK,36,T657,gp41,CEM,128,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP814,HSLIEESQNQQEKNEQELLELDKWASLWNWFNITNW,36,T635,gp41,CEM,139,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP822,LIEESQNQQEKNEQELLELDKWASLWNWFNITNWLW,36,T633,gp41,CEM,186,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP821,LEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQE,36,T658,gp41,CEM,191,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP820,KSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQ,36,T660,gp41,CEM,258,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP828,NKSLEQIWNNMTWMEWDREINNYTSLIHSLIEESQN,36,T661,gp41,CEM,297,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP826,MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,36,T651,gp41,CEM,338,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP870,YTSLIHSLIEESQNQQEKNEQELLELDKPASLWNWF,36,T704,gp41,CEM,510,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP839,SLIEESQNQQEKNEQELLELDKWASLWNWFNITNWL,36,T634,gp41,CEM,554,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP893,YTSLIHSLIQQSQNQQQKNQQQLLQLDKWASLWNWF,36,T216,gp41,CEM,1000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP818,INNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,36,T642,gp41,CEM,1450,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP810,EINNYTSLIHSLIEESQNQQEKNEQELLELDKWASL,36,T643,gp41,CEM,1690,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP838,SLEQIWNNMTWMEWDREINNYTSLIHSLIEESQNQQ,36,T659,gp41,CEM,2290,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP819,IWNNMTWMEWDREINNYTSLIHSLIEESQNQQEKNE,36,T655,gp41,CEM,2300,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP836,REINNYTSLIHSLIEESQNQQEKNEQELLELDKWAS,36,T644,gp41,CEM,4960,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP816,IEESQNQQEKNEQELLELDKWASLWNWFNITNWLWL,36,T632,gp41,CEM,101800,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP832,NQQEKNEQELLELDKWASLWNWFNITNWLWLIKIFI,36,T627,gp41,CEM,>1000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP835,QNQQEKNEQELLELDKWASLWNWFNITNWLWLIKIF,36,T628,gp41,CEM,>1000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP841,SQNQQEKNEQELLELDKWASLWNWFNITNWLWLIKI,36,T629,gp41,CEM,>1000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP812,ESQNQQEKNEQELLELDKWASLWNWFNITNWLWLIK,36,T630,gp41,CEM,>1000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP808,EESQNQQEKNEQELLELDKWASLWNWFNITNWLWLI,36,T631,gp41,CEM,>1000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP871,YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA,36,T229,gp41,CEM,>100000,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP888,YTSLIHSLIEEVQNQQEKNEQELLELDKWASLWNWF,36,T-20S138V,Enfuvirtide,HeLa,0.4±0.2(0.2),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP859,YTSLIHSLIEEIQNQQEKNEQELLELDKWASLWNWF,36,T-20S138I,Enfuvirtide,HeLa,0.5±0.1(0.2),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP853,YTSLIHSLIEEAQNQQEKNEQELLELDKWASLWNWF,36,T-20S138A,Enfuvirtide,HeLa,0.6±0.1(0.3),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP861,YTSLIHSLIEELQNQQEKNEQELLELDKWASLWNWF,36,T-20S138L,Enfuvirtide,HeLa,0.7±0.1(0.3),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP862,YTSLIHSLIEEMQNQQEKNEQELLELDKWASLWNWF,36,T-20S138M,Enfuvirtide,HeLa,0.7±0.2(0.3),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP887,YTSLIHSLIEETQNQQEKNEQELLELDKWASLWNWF,36,T-20S138T,Enfuvirtide,HeLa,0.9±0.2(0.4),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP857,YTSLIHSLIEEGQNQQEKNEQELLELDKWASLWNWF,36,T-20S138G,Enfuvirtide,HeLa,1.3±0.5(0.5),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP863,YTSLIHSLIEENQNQQEKNEQELLELDKWASLWNWF,36,T-20S138N,Enfuvirtide,HeLa,19±4(8),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP878,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T-20,Enfuvirtide,HeLa,2.4±0.6,nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP858,YTSLIHSLIEEHQNQQEKNEQELLELDKWASLWNWF,36,T-20S138H,Enfuvirtide,HeLa,210±85(88),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP854,YTSLIHSLIEEDQNQQEKNEQELLELDKWASLWNWF,36,T-20S138D,Enfuvirtide,HeLa,210±94(88),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP890,YTSLIHSLIEEYQNQQEKNEQELLELDKWASLWNWF,36,T-20S138T,Enfuvirtide,HeLa,25±9(10),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP855,YTSLIHSLIEEEQNQQEKNEQELLELDKWASLWNWF,36,T-20S138E,Enfuvirtide,HeLa,283±80(118),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP889,YTSLIHSLIEEWQNQQEKNEQELLELDKWASLWNWF,36,T-20S138W,Enfuvirtide,HeLa,29±14(12),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP865,YTSLIHSLIEEQQNQQEKNEQELLELDKWASLWNWF,36,T-20S138,Enfuvirtide,HeLa,34±11(14),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP866,YTSLIHSLIEERQNQQEKNEQELLELDKWASLWNWF,36,T-20S138Q,Enfuvirtide,HeLa,362±114(150),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP864,YTSLIHSLIEEPQNQQEKNEQELLELDKWASLWNWF,36,T-20S138P,Enfuvirtide,HeLa,446±167(186),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP860,YTSLIHSLIEEKQNQQEKNEQELLELDKWASLWNWF,36,T-20S138K,Enfuvirtide,HeLa,708±145(295),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP856,YTSLIHSLIEEFQNQQEKNEQELLELDKWASLWNWF,36,T-20S138F,Enfuvirtide,HeLa,9.4±2.6(4),nM(fold),Fusion inhibitor,MAGI assay,19073606,Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.,Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M.,J Biol Chem. 2009 Feb 20;284(8):4914-20. Epub 2008 Dec 10.,,,,,,,,
HIP1087,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T20,CCR5,MT-4,High,NA,Fusion inhibitor,MTT assay,17210123,Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.,Imai M, Baranyi L, Okada N, Okada H.,Biochem Biophys Res Commun. 2007 Feb 23;353(4):851-6. Epub 2006 Dec 21.,,,,,,,,,,,,,,,,,,
HIP827,MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,36,651,Synthetic,CEM4,0.033,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP879,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,ENF (T-20),Synthetic,CEM4,0.05,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP1130,SGIDQEQNNLTRLIEAQIHELQLTQWKIKQLLARILK,37,N36,gp41,TZM-bl,488,nM,Fusion inhibitor,Flow Cytometry,19593361,Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.,Wexler-Cohen Y, Shai Y.,PLoS Pathog. 2009 Jul;5(7):e1000509. Epub 2009 Jul 10.,,,,,,,,,,,,,,,,,,,,
HIP1131,SGIVQQLNNQLRAEEANQHLEQLSVWGSKQNQARRLK,37,N36M,gp41,TZM-bl,531,nM,Fusion inhibitor,Flow Cytometry,19593361,Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action.,Wexler-Cohen Y, Shai Y.,PLoS Pathog. 2009 Jul;5(7):e1000509. Epub 2009 Jul 10.,,,,,,,,,,,,,,,,,,,,
HIP898,GFSSIFRGVAKFASKGLGKDLARLGVNLVACKISKQC,37,Esculentin-2P,Rana pipiens,T cells,30,%,Fusion inhibitor,GFP expression,16140737,Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.,J Virol. 2005 Sep;79(18):11598-606.,,,,,,,,
HIP902,WMEWDREIEELAKKAEELAKKAEELAKKAWASLWNWF,37,PBD-3HRa-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP901,WMEWDREIEEAAKKLEEAAKKLEEAAKKLWASLWNWF,37,PBD-3HRb-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP900,WMEWDREIEALAKAAEALAKAAEALAKAAWASLWNWF,37,PBD-3HRc-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP903,WMEWDREIEEYTKKIEEYTKKIEEYTKKIWASLWNWF,37,PBD-3HR-LBD,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1171,FWNWLSAWIKKTYEEIKKTYEEIKKTYEEIERDWEMV,37,PBD-3HR-LBD,Synthetic,H9/HIV-1I,0.58,μM,Fusion inhibitor,ELISA,18662985,Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.,Qi Z, Shi W, Xue N, Pan C, Jing W, Liu K, Jiang S.,J Biol Chem. 2008 Oct 31;283(44):30376-84. Epub 2008 Jul 28.,,,,,,,,,,,,,,,
HIP925,TTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,38,C38,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP908,NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ,38,DP-107,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP923,TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL,38,T-1144,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP914,TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL,38,T2635,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP911,TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL,38,T267227,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP907,NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ,38,T21,gp41,CEM,2,ng/ml,Fusion inhibitor,RT production,US6861059,Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations,M. Ross Johnson, Dennis Michael Lambert,Trimeris, Inc.,,,,,,,,,,,,,,,,,,,
HIP922,TTWEAWDRAIAEYAARIEALIRASQEQQEKNEAELREL,38,290676,Synthetic,CEM4,0.013,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP915,TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL,38,2635,Synthetic,CEM4,0.018,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP924,TTWEEWDREINEYTSRIESLIRESQEQQEKNEQELREL,38,2429,Synthetic,CEM4,0.021,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP916,TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAILREL,38,267209,Synthetic,CEM4,0.021,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP910,TTWEAWDRAIAEYAARIEALIRAAQELQEKNEAALREL,38,267226,Synthetic,CEM4,0.021,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP904,MTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL,38,2544,Synthetic,CEM4,0.026,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP906,MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,38,2410,Synthetic,CEM4,0.032,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP920,TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAALREL,38,267221,Synthetic,CEM4,0.035,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP921,TTWEAWDRAIAEYAARIEALIRALQEQQEKNEAILREL,38,267225,Synthetic,CEM4,0.043,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP912,TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAALREL,38,267227,Synthetic,CEM4,0.045,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP913,TTWEAWDRAIAEYAARIEALIRAAQEQQEKLEAVLREL,38,291022,Synthetic,CEM4,0.049,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP918,TTWEAWDRAIAEYAARIEALIRALQELQEKNEAALREL,38,290822,Synthetic,CEM4,0.054,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP905,MTWMAWDRAIANYAALIHALIEAAQNQQEKNEAALLEL,38,2638,Synthetic,CEM4,0.079,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP919,TTWEAWDRAIAEYAARIEALIRALQELQEKNEAILREL,38,290821,Synthetic,CEM4,0.118,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP909,TTWEAWDRAIAEYAARIEALIRAAQELQEKLEAALREL,38,267228,Synthetic,CEM4,0.6,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP917,TTWEAWDRAIAEYAARIEALIRALQELQEKLEAILREL,38,267229,Synthetic,CEM4,>20,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP926,WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF,39, T-1249 ,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP927,WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASL WEWF,40,1249,Synthetic,CEM4,0.013,μg/ml,Fusion inhibitor,MAGI/cMAGI infectivity assay,17640899,Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.,Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK.,Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12772-7. Epub 2007 Jul 19.,,,,,,,,,,,
HIP1112,IVHVTAKDKGTGKENTIRIQEGSGLSKEDIDRMIKDAEAH,40,p457-496,HSP70,PM-1,Low,NA,Fusion inhibitor,RT assay,17251296,Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426.,Babaahmady K, Oehlmann W, Singh M, Lehner T.,J Virol. 2007 Apr;81(7):3354-60. Epub 2007 Jan 24.,,,,,,,,,,,,,,,,,,
HIP1116,EWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLW,41,WT,gp41,CHO-WT,1.5,nM,Fusion inhibitor,Syncytia assay,22770564,Site-Specific PEGylation of HR2 Peptides: Effects of PEG Conjugation Position and Chain Length on HIV-1 Membrane Fusion Inhibition and Proteolytic Degradation.,Danial M, van Dulmen TH, Aleksandrowicz J, Potgens AJ, Klok HA.,Bioconjug Chem. 2012 Aug 15;23(8):1648-60. Epub 2012 Jul 25.,,,,,,,,,,,,,,,,,
HIP928,NHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKW,43,C43,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP930,GIFPKIIGKGIVNGIKSLAKGVGMKVFKAGLNNIGNTGCNNRDEC,45,Palustrin-3AR,Rana areolata,T cells,30,%,Fusion inhibitor,GFP expression,16140737,Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.,J Virol. 2005 Sep;79(18):11598-606.,,,,,,,,
HIP929,CDGGIKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL,45,ccIZN17,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP931,RMKQIEDKIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL,45,IQN17,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP932,GLFPKFNKKKVKTGIFDIIKTVGKEAGMDVLRTGIDVIGCKIKGEC,46,Esculentin-1ARb,Rana areolata,T cells,35,%,Fusion inhibitor,GFP expression,16140737,Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.,VanCompernolle SE, Taylor RJ, Oswald-Richter K, Jiang J, Youree BE, Bowie JH, Tyler MJ, Conlon JM, Wade D, Aiken C, Dermody TS, KewalRamani VN, Rollins-Smith LA, Unutmaz D.,J Virol. 2005 Sep;79(18):11598-606.,,,,,,,,
HIP934,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,46,C46,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP933,TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,46,N46,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP936,SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQCCGRISGIVQQQNNLLRA,48,N35ccg-N13,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP937,QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKQQ,51,N51,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP938,IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARILAVERY,53,IZN28,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP939,NHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNIKIL,55,C52L,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP1132,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNITNWLWYIK,56,P5,gp41,HeLa,60,nM,Fusion inhibitor,Cell-to-cell fusion assay,18925934,Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.,Yu H, Tudor D, Alfsen A, Labrosse B, Clavel F, Bomsel M.,Retrovirology. 2008 Oct 16;5:93.,,,,,,,,,,,,,,
HIP1119,IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,62,IZN36 ,gp41,293T,35,nM,Fusion inhibitor,Pseudovirus assay,22235115,Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.,Zhuang M, Wang W, De Feo CJ, Vassell R, Weiss CD.,J Biol Chem. 2012 Mar 9;287(11):8297-309. Epub 2012 Jan 10.,,,,,,,,,,,,,,,,
HIP940,IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,62,IZN36,Synthetic,NA,Medium,NA,Fusion inhibitor,CD spectra,US7919101,Highly potent synergistic combinations of human immunodeficiency virus (HIV) fusion inhibitors,Shibo Jiang, Chungen Pan,New York Blood Center,,,,,,,,,,,,,,,,,,,,
HIP960,GIGAVLKVLTTGLPALISWIKRKRQQ,26,Melittin,Melittin,Hut-78,0.9 to 1.5,μM,Gene expression,RT-PCR,9568968,Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression.,Wachinger M, Kleinschmidt A, Winder D, von Pechmann N, Ludvigsen A, Neumann M, Holle R, Salmons B, Erfle V, Brack-Werner R.,J Gen Virol. 1998 Apr;79 ( Pt 4):731-40.,,,,,,,,,,,,
HIP961,KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK,37,Cecropin,Cecropin,Hut-78,2 to 3,μM,Gene expression,RT-PCR,9568968,Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression.,Wachinger M, Kleinschmidt A, Winder D, von Pechmann N, Ludvigsen A, Neumann M, Holle R, Salmons B, Erfle V, Brack-Werner R.,J Gen Virol. 1998 Apr;79 ( Pt 4):731-40.,,,,,,,,,,,,
HIP26,IKQEF,5,NL9-7 ,Synthetic,NA,>100,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP1128,LQQLLF,6,Vpr-1,vpr,MT-4,68?,nM,Integrase,Luciferase assay,20586421,Peptide HIV-1 integrase inhibitors from HIV-1 gene products.,Suzuki S, Urano E, Hashimoto C, Tsutsumi H, Nakahara T, Tanaka T, Nakanishi Y, Maddali K, Han Y, Hamatake M, Miyauchi K, Pommier Y, Beutler JA, Sugiura W, Fuji H, Hoshino T, Itotani K, Nomura W, Narumi T, Yamamoto N, Komano JA, Tamamura H.,J Med Chem. 2010 Jul 22;53(14):5356-60.
HIP75,HCKFWW,6,19,Synthetic,E.coli,2,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP36,HCKAWW,6,25,Synthetic,E.coli,8,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP43,HCKFWD,6,5,Synthetic,E.coli,18,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP46,HCKFWE,6,7,Synthetic,E.coli,28,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP61,HCKFWN,6,4,Synthetic,E.coli,30,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP41,HCKFWC,6,6,Synthetic,E.coli,30,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP34,HAKFWW,6,23,Synthetic,E.coli,30,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP56,HCKFWK,6,13,Synthetic,E.coli,34,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP69,HCKFWS,6,17,Synthetic,E.coli,40,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP60,HCKFWM,6,14,Synthetic,E.coli,42,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP64,HCKFWP,6,16,Synthetic,E.coli,45,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP35,HCAFWW,6,24,Synthetic,E.coli,49,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP30,ACKFWW,6,22,Synthetic,E.coli,51,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP52,HCKFWH,6,10,Synthetic,E.coli,72,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP78,HCKFWY,6,20,Synthetic,E.coli,75,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP50,HCKFWG,6,9,Synthetic,E.coli,82,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP73,HCKFWV,6,21,Synthetic,E.coli,85,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP68,HCKFWR,6,3,Synthetic,E.coli,88,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP48,HCKFWF,6,15,Synthetic,E.coli,95,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP54,HCKFWI,6,11,Synthetic,E.coli,96,%,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP37,HCKFAW,6,26,Synthetic,E.coli,150,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP38,HCKFWA,6,27,Synthetic,E.coli,210,μM,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP66,HCKFWQ,6,8,Synthetic,E.coli,Low,NA,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP57,HCKFWL,6,12,Synthetic,E.coli,Low,NA,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP72,HCKFWT,6,18,Synthetic,E.coli,Low,NA,Integrase,Autoradiography,US5578573,Viral integrase inhibiting peptides,Richard A. Houghten, Patricia A. Weber, Ronald H. A. Plasterk, Ramon A. Puras Lutzke,Houghten Pharmaceuticals, Inc.,,,,,,,,,,,,,,,,,
HIP44,HCKFWD,6,-,Synthetic,NA,18,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP45,HCKFWE,6,-,Synthetic,NA,24,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP42,HCKFWC,6,-,Synthetic,NA,30,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP55,HCKFWK,6,-,Synthetic,NA,30,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP62,HCKFWN,6,-,Synthetic,NA,30,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP59,HCKFWM,6,-,Synthetic,NA,40,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP70,HCKFWS,6,-,Synthetic,NA,40,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP63,HCKFWP,6,-,Synthetic,NA,42,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP51,HCKFWH,6,-,Synthetic,NA,69,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP79,HCKFWY,6,-,Synthetic,NA,78,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP49,HCKFWG,6,-,Synthetic,NA,79,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP58,HCKFWL,6,-,Synthetic,NA,83,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP74,HCKFWV,6,-,Synthetic,NA,85,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP47,HCKFWF,6,-,Synthetic,NA,92,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP53,HCKFWI,6,-,Synthetic,NA,92,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP77,HCKFWW,6,-,Synthetic,NA,100,%,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP39,HCKFWA,6,-,Synthetic,NA,Low,NA,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP65,HCKFWQ,6,-,Synthetic,NA,Low,NA,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP67,HCKFWR,6,-,Synthetic,NA,Low,NA,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP71,HCKFWT,6,-,Synthetic,NA,Low,NA,Integrase,Integration assay,8524782,Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library.,Puras Lutzke RA, Eppens NA, Weber PA, Houghten RA, Plasterk RH.,Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11456-60.,,,,,,,,,,,,,,,,,
HIP88,YFLLKL,6,NL6-5 ,Synthetic,NA,20,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP84,TAYFLL,6,NL6-4,Synthetic,NA,500,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP81,KLAGRW,6,NL6-6,Synthetic,NA,>100,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP31,ACWWAG,6,NL9-5 ,Synthetic,NA,>100,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP87,WAGIKQ,6,NL9-6 ,Synthetic,NA,>100,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP1145,HCKFWW,6,-,Synthetic,NA,90,μM,Integrase,Integrase Assay,12951093,Design and synthesis of dimeric HIV-1 integrase inhibitory peptides.,Krajewski K, Long YQ, Marchand C, Pommier Y, Roller PP.,Bioorg Med Chem Lett. 2003 Oct 6;13(19):3203-5.,,,,,,,,,,,,,,,,,
HIP83,NPRLYE,6,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP106,VHVASGY,7,NL4,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP89,GRWPVKT,7,NL7,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP1165,DLHTHAQ,7,-,Marine polychaete,NA,30,μM,Integrase,Integrase Assay,21721256,[Isolation and structure of novel peptide inhibitor of HIV-1 integrase from marine polychaetes].,Eliakova LA, Vas'kovskii BV, Khoroshilova NI, Vantseva SI, Agapkina IuIu,Bioorg Khim. 2011 Mar-Apr;37(2):233-43. Russian.,,,,,,,,,,,,,,,,,
HIP104,STPIPAP,7,-,Phage display,NA,>10^12,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP113,FHNHGAP,7,-,Phage display,NA,>10^12,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP117,FHNHGST,7,-,Phage display,NA,>10^12,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP99,RLFTWEG,7,-,Phage display,NA,>10^12,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP92,HIEHLIA,7,-,Phage display,NA,10^10,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP93,HLEHLLF,7,-,Phage display,NA,10^10,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP116,FHNHGKQ,7,-,Phage display,NA,10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP102,SSLPLRK,7,-,Phage display,NA,10^12,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP103,STFTHPR,7,-,Phage display,NA,5*10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP112,FHNHGAA,7,-,Phage display,NA,5*10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP114,FHNHGAT,7,-,Phage display,NA,5*10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP115,FHNHGIL,7,-,Phage display,NA,5*10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP97,PFFHLIG,7,-,Phage display,NA,5*10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP111,FHGHGLY,7,-,Phage display,NA,7*10^11,FC50(pfu/mL),Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP100,SLLSSPQ,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP101,SPYHTQP,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP105,TTYSRFP,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP107,VPTGYKP,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP109,AEPVAML,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP110,ASSRTPS,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP118,FHQNWPS,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP90,HAWNYIF,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP91,HFWNRPL,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP94,HWGMWSY,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP95,LPPNPTN,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP96,NSHAIYP,7,-,Phage display,NA,Low,NA,Integrase,ELISA,15476403,Identification by phage display selection of a short peptide able to inhibit only the strand transfer reaction catalyzed by human immunodeficiency virus type 1 integrase.,Desjobert C, de Soultrait VR, Faure A, Parissi V, Litvak S, Tarrago-Litvak L, Fournier M.,Biochemistry. 2004 Oct 19;43(41):13097-105.,,,,,,,,,,,,,,,
HIP98,QLLIRMI,7,LCD278C,Synthetic,HeLa,>200,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP1042,GYIEAEVI,8,beta3,Integrase,NA,>1,mM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP1049,SLKIPNLD,8,-,LEDGF/p75,NA,High,NA,Integrase,Alpha screen assay,21850718,Crystal Structures of Novel Allosteric Peptide Inhibitors of HIV Integrase Identify New Interactions at the LEDGF Binding Site.,Rhodes DI, Peat TS, Vandegraaff N, Jeevarajah D, Newman J, Martyn J, Coates JA, Ede NJ, Rea P, Deadman JJ.,Chembiochem. 2011 Oct 17;12(15):2311-5. doi: 10.1002/cbic.201100350. Epub 2011 Aug 17.,,,,,,,,,,,,
HIP122,FIHNFKRK,8,NL13,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP133,PAETGQET,8,NL5,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP127,HTDNGSNF,8,NL8,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP138,YQLLIRMI,8,LCE40,Synthetic,HeLa,120,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP148,YQLLIRMIY,9,LCE41,Synthetic,HeLa,5,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP1137,AGERIVDIIA,10,alpha6S,Integrase,NA,30,μM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP1018,WQCLTLTHRG,10,IN1 1–10 ,Synthetic,HeLa,68,%,Integrase,MAGI Assay,19850483,Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.,Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A.,Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. Epub 2009 Oct 4.,,,,,,,,,,,,,,,,
HIP152,FGIPYNPQSQ,10,NL10,Synthetic,NA,>1000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP156,WKGPAKLLWK,10,NL15,Synthetic,NA,>1000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP150,EEHEKYHSNW,10,NL1,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP151,ESMNKELKKI,10,NL11,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP155,VRDQAEHLKT,10,NL12,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP153,GYSAGERIVD,10,NL14,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP149,ASCDKCQLKG,10,NL2,Synthetic,NA,>2000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP154,LFYLVPGPGH,10,EBR26,Synthetic,HeLa,>200,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP1043,STTVKAASWWA,11,alpha3,Integrase,NA,>1,mM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP1115,WNSLKIDNLDV,11,LEDGF-(360–370),LEDGF/p75,NA,11900,nM,Integrase,Integrase Assay,19801648,Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex.,Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R.,J Biol Chem. 2009 Nov 27;284(48):33580-99. Epub 2009 Sep 28.,,,,,,,,
HIP1053,LKTVRLIKFLY,11,Rev13-23,rev,TZM-bl,High,NA,Integrase,MAGI Assay,17403681,Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.,Rosenbluh J, Hayouka Z, Loya S, Levin A, Armon-Omer A, Britan E, Hizi A, Kotler M, Friedler A, Loyter A.,J Biol Chem. 2007 May 25;282(21):15743-53. Epub 2007 Apr 2.,,,,,,,,,,,,
HIP170,ACWWAGIKQEF,11,DNL-9 ,Synthetic,NA,>1000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP161,ACWGAGIKQEF,11,NL9-3 ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP171,ACWWAGIRQEF,11,NL9-4 ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP166,ACWWAGIKQAF,11,NL9-E10A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP163,ACWWAGAKQEF,11,NL9-I7A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP165,ACWWAGIKAEF,11,NL9-Q9A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP160,ACWAAGIKQEF,11,NL9-W4A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP167,ACWWAGIKQEA,11,NL9-F11A ,Synthetic,NA,245±13,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP157,AAWWAGIKQEF,11,NL9-C2A ,Synthetic,NA,277±47,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP174,ASWWAGIKQEF,11,NL9-1 ,Synthetic,NA,294±41,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP158,ACAWAGIKQEF,11,NL9-W3A ,Synthetic,NA,33±6,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP159,ACGWAGIKQEF,11,NL9-2 ,Synthetic,NA,46±5,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP164,ACWWAGIAQEF,11,NL9-K8A ,Synthetic,NA,62±13,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP162,ACWWAAIKQEF,11,NL9-G6A ,Synthetic,NA,90±10,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP168,ACWWAGIKQEF,11,NL-9 ,Synthetic,NA,95±9,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP1110,LKTVRLIKFLY,11,Rev 13-23,rev,NA,High,NA,Integrase,Integrase Assay,18219678,Peptides derived from HIV-1 Rev inhibit HIV-1 integrase in a shiftide mechanism.,Hayouka Z, Rosenbluh J, Levin A, Maes M, Loyter A, Friedler A.,Biopolymers. 2008;90(4):481-7.,,,,,,,,,,,,,,,,
HIP1031,WNSLKIANLAV,11,D366/369A ,LEDGF/p75,Sup-T1,43,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1027,WNSLKIANLDV,11,D366A,LEDGF/p75,Sup-T1,58,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1026,WNSLKADNLDV,11,I365A,LEDGF/p75,Sup-T1,65,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1030,WNSLKIDNLDA,11,V370A,LEDGF/p75,Sup-T1,68,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1025,WNSAKIDNLDV,11,L363A,LEDGF/p75,Sup-T1,71,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1029,WNSLKIDNADV,11,L368A,LEDGF/p75,Sup-T1,75,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1028,WNSLKIDALDV,11,N367A,LEDGF/p75,Sup-T1,75,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1023,WASLKIDNLDV,11,N361A,LEDGF/p75,Sup-T1,76,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1024,WNALKIDNLDV,11,S362A,LEDGF/p75,Sup-T1,79,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1022,WNSLKIDNLDV,11,LEDGF 361–370,LEDGF/p75,Sup-T1,81,%,Integrase,Fluorescence anisotropy,20171172,Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370.,Hayouka Z, Levin A, Maes M, Hadas E, Shalev DE, Volsky DJ, Loyter A, Friedler A.,Biochem Biophys Res Commun. 2010 Apr 2;394(2):260-5. Epub 2010 Feb 18.,,,,,,,,,,,,,,
HIP1050,WNSLKIDNLDV,11,LEDGF 361–370 ,LEDGF/p75,NA,High,NA,Integrase,Integrase Assay,20974536,Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein.,Hayouka Z, Hurevich M, Levin A, Benyamini H, Iosub A, Maes M, Shalev DE, Loyter A, Gilon C, Friedler A.,Bioorg Med Chem. 2010 Dec 1;18(23):8388-95. Epub 2010 Oct 1.,,,,,,,,,,,,
HIP178,QLLIRMIYKNI,11,LCD278C,Synthetic,HeLa,21,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP173,AEPERRNIKYL,11,EBR24,Synthetic,HeLa,50,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP199,TAYALLKLAGRW,12,NL6-F4A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP201,TAYFLAKLAGRW,12,NL6-L6A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP204,TAYFLLKAAGRW,12,NL6-L8A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP207,TAYFLLKLAGRA,12,NL6-W12A ,Synthetic,NA,>333,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP179,AAYFLLKLAGRW,12,NL6-T1A ,Synthetic,NA,100±10,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP202,TAYFLLALAGRW,12,NL6-K7A ,Synthetic,NA,113±15,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP200,TAYFALKLAGRW,12,NL6-L5A ,Synthetic,NA,115±21,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP205,TAYFLLKLAARW,12,NL6-G10A ,Synthetic,NA,118±10,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP198,TASFLLKLAGRW,12,NL6-1 ,Synthetic,NA,186±23,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP197,TAAFLLKLAGRW,12,NL6-Y3A ,Synthetic,NA,193±10,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP209,TAYFLLKLAGRW,12,NL-6 ,Synthetic,NA,21±7,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP208,TAYFLLKLAGRL,12,NL6-3 ,Synthetic,NA,315±30,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP203,TAYFLLILAGRW,12,NL6-2 ,Synthetic,NA,4.1±0.7,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP210,TAYFLLKLAGRW,12,DNL-6,Synthetic,NA,65±8,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP206,TAYFLLKLAGAW,12,NL6-R11A ,Synthetic,NA,83±15,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP231,YQLLIRMIYKNI,12,EBR28,Synthetic,HeLa,5,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP229,YQLLIRMIYKAI,12,N11A,Synthetic,HeLa,7,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP218,YALLIRMIYKNI,12,Q2A,Synthetic,HeLa,8,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP230,YQLLIRMIYKNA,12,I12A,Synthetic,HeLa,11,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP228,YQLLIRMIYANI,12,K10A,Synthetic,HeLa,11,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP222,YQLAIRMIYKNI,12,L4A,Synthetic,HeLa,14,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP224,YQLLIAMIYKNI,12,R6A,Synthetic,HeLa,34,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP226,YQLLIRMAYKNI,12,I8A,Synthetic,HeLa,35,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP227,YQLLIRMIAKNI,12,Y9A,Synthetic,HeLa,40,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP223,YQLLARMIYKNI,12,I5A,Synthetic,HeLa,45,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP225,YQLLIRAIYKNI,12,M7A,Synthetic,HeLa,70,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP221,YQALIRMIYKNI,12,L3A,Synthetic,HeLa,165,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP232,YQLLIRPIYKNI,12,ProEBR28,Synthetic,HeLa,>200,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP1136,QETAYFLLKLAGR,13,alpha1S,Integrase,NA,150,μM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP1060,ILPWKWPWWPWPP,13,RIN-25,Indolicidin,NA,60,μM,Integrase,Schiff base assay,16998183,Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites.,Marchand C, Krajewski K, Lee HF, Antony S, Johnson AA, Amin R, Roller P, Kvaratskhelia M, Pommier Y.,Nucleic Acids Res. 2006;34(18):5157-65. Epub 2006 Sep 22.,,,,,,,,,,,,,
HIP1147,ILPWKWPWWPWPP,13,Indolicidin,Indolicidin,NA,16,μM,Integrase,Integrase Assay,15482931,Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin.,Krajewski K, Marchand C, Long YQ, Pommier Y, Roller PP.,Bioorg Med Chem Lett. 2004 Nov 15;14(22):5595-8.,,,,,,,,,,,,,,,,,
HIP1048,WKKIRRFVSQVIM,13,p75 402–411,LEDGF/p75,HeLa,High,NA,Integrase,Gel filtration,17488811,Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.,Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, Veprintsev D, Kotler M, Hizi A, Loyter A, Friedler A.,Proc Natl Acad Sci U S A. 2007 May 15;104(20):8316-21. Epub 2007 May 8.,,,,,,,,,,,,
HIP1135,AGERIVDIIATDIQ,14,alpha6,Integrase,NA,2,μM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP271,NQIIEQLIKKEKVY,14,4321’-1,Reverse Transcriptase,NA,>240,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP267,AWVPAHKGIGGNEQ,14,5633,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP1059,ILPWKWPWWPWRR,14,Indolicidin,Indolicidin,NA,60,μM,Integrase,Schiff base assay,16998183,Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites.,Marchand C, Krajewski K, Lee HF, Antony S, Johnson AA, Amin R, Roller P, Kvaratskhelia M, Pommier Y.,Nucleic Acids Res. 2006;34(18):5157-65. Epub 2006 Sep 22.,,,,,,,,,,,,,
HIP1133,QETAYFLLKLAGRWP,15,alpha1,Integrase,NA,3.5,μM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP1056,AGVEAIIRILQQLLF,15,1,vpr,MT-4,High,NA,Integrase,Luciferase assay,20708407,Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5. Epub 2010 Jul 25.,,,,,,,
HIP1057,IIRILQQLLFIHFRI,15,2,vpr,MT-4,High,NA,Integrase,Luciferase assay,20708407,Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5. Epub 2010 Jul 25.,,,,,,,
HIP1055,RSISGWILSTYLGRP,15,Rev53-67 ,rev,TZM-bl,High,NA,Integrase,MAGI Assay,17403681,Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.,Rosenbluh J, Hayouka Z, Loya S, Levin A, Armon-Omer A, Britan E, Hizi A, Kotler M, Friedler A, Loyter A.,J Biol Chem. 2007 May 25;282(21):15743-53. Epub 2007 Apr 2.,,,,,,,,,,,,
HIP293,FRKQNPDIVIYQYMD,15,4286’-1,Reverse Transcriptase,NA,119,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP288,ESELVSQIIEQLIKK,15,5628,Reverse Transcriptase,NA,>120,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP318,KGSPAIFQSSMTKIL,15,5538,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP274,AIFQSSMTKILEPFR,15,5539,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP359,SSMTKILEPFRKQNP,15,5540,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP319,KILEPFRKQNPDIVI,15,5541,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP336,PFRKQNPDIVIYQYM,15,5542,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP343,QNPDIVIYQYMDDLY,15,5543,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP311,IVIYQYMDDLYVGSD,15,5544,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP347,QYMDDLYVGSDLEIG,15,5545,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP306,IQAQPDKSESELVSQ,15,5626,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP334,PDKSESELVSQIIEQ,15,5627,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP373,VSQIIEQLIKKEKVY,15,5629,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP302,IEQLIKKEKVYLAWV,15,5630,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP304,IKKEKVYLAWVPAHK,15,5631,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP322,KVYLAWVPAHKGIGG,15,5632,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP294,FRKQNPDIVIYQYMD,15,4286’-1,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP1111,RSISGWILSTYLGRP,15,Rev 53-67,rev,NA,High,NA,Integrase,Integrase Assay,18219678,Peptides derived from HIV-1 Rev inhibit HIV-1 integrase in a shiftide mechanism.,Hayouka Z, Rosenbluh J, Levin A, Maes M, Loyter A, Friedler A.,Biopolymers. 2008;90(4):481-7.,,,,,,,,,,,,,,,,
HIP308,IRILQQLLFIHFRIG,15,Vpr 61-75,vpr,NA,1.3,μM,Integrase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP368,VEAIIRILQQLLFIH,15,Vpr 57-71,vpr,NA,7.8,μM,Integrase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP345,QQLLFIHFRIGCQHS,15,Vpr 65-79 ,vpr,NA,76,μM,Integrase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP300,HFPRIWLHSLGQHIY,15,Vpr 33-47 ,vpr,NA,187,μM,Integrase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP292,FIHFRIGCQHSRIGI,15,Vpr 69-83,vpr,NA,>>200,μM,Integrase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP362,TWAGVEAIIRILQQL,15,Vpr 53-67,vpr,NA,>200,μM,Integrase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP1058,LQQLLFIHFRIGCQH,16,3,vpr,MT-4,High,NA,Integrase,Luciferase assay,20708407,Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies.,Suzuki S, Maddali K, Hashimoto C, Urano E, Ohashi N, Tanaka T, Ozaki T, Arai H, Tsutsumi H, Narumi T, Nomura W, Yamamoto N, Pommier Y, Komano JA, Tamamura H.,Bioorg Med Chem. 2010 Sep 15;18(18):6771-5. Epub 2010 Jul 25.,,,,,,,
HIP1102,RQIKIWFQNRRMKWKK,16,Ant 43-58,Integrase,TZM-bl,High,NA,Integrase,RT-PCR,19961612,Inhibition of HIV-1 integrase nuclear import and replication by a peptide bearing integrase putative nuclear localization signal.,Levin A, Armon-Omer A, Rosenbluh J, Melamed-Book N, Graessmann A, Waigmann E, Loyter A.,Retrovirology. 2009 Dec 5;6:112.,,,,,,,,,,,,,,,
HIP1134,HLKTAVQMAVFIHNFKR,17,alpha5,Integrase,NA,3,μM,Integrase,Integrase Assay,12643937,Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization.,Zhao L, O'Reilly MK, Shultz MD, Chmielewski J.,Bioorg Med Chem Lett. 2003 Mar 24;13(6):1175-7.,,,,,,,,,,,,,,,,,,
HIP1138,ATGQETAYFLLKLAGKA,17,INH1,Integrase,NA,250,μM,Integrase,Integrase Assay,11705373,Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers.,Maroun RG, Gayet S, Benleulmi MS, Porumb H, Zargarian L, Merad H, Leh H, Mouscadet JF, Troalen F, Fermandjian S.,Biochemistry. 2001 Nov 20;40(46):13840-8.,,,,,,,,,,,,
HIP404,HGQVDCSPGIWQLDCTH,17,NL3 ,Synthetic,NA,1000,μM,Integrase,Integrase Assay,16854053,Sequence-based design and discovery of peptide inhibitors of HIV-1 integrase: insight into the binding mode of the enzyme.,Li HY, Zawahir Z, Song LD, Long YQ, Neamati N.,J Med Chem. 2006 Jul 27;49(15):4477-86.,,,,,,,,,,,,,,,,,
HIP1044,ATGQETAYFLLKLALKA,18,-,Integrase,NA,High,NA,Integrase,Integrase Assay,17281301,Peptides design based on the interfacial helix of integrase dimer.,Kong R, Wang C, Ma X, Liu J, Chen W.,Conf Proc IEEE Eng Med Biol Soc. 2005;5:4743-6.,,,,,,,,,,,,,,,,,
HIP552,IKKEKVYLAWVPAHKGIGN,19,4322,Reverse Transcriptase,NA,>120,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP1142,ETWETWWTEYWQATWIPEWE,20,56,pol,NA,6,μM,Integrase,Integrase Assay,16879966,Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.,Zawahir Z, Neamati N.,Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. Epub 2006 Aug 1.,,,,,,,,,,,,,,,,,,,,
HIP1141,KQLTEAVQKITTESIVIWGK,20,53,pol,NA,7,μM,Integrase,Integrase Assay,16879966,Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.,Zawahir Z, Neamati N.,Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. Epub 2006 Aug 1.,,,,,,,,,,,,,,,,,,,,
HIP1143,LQDSGLEVNIVTDSQYALGI,20,65,pol,NA,11,μM,Integrase,Integrase Assay,16879966,Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.,Zawahir Z, Neamati N.,Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. Epub 2006 Aug 1.,,,,,,,,,,,,,,,,,,,,
HIP1144,ELVNQIIEQLIKKEKVYLAW,20,64,pol,NA,15,μM,Integrase,Integrase Assay,16879966,Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.,Zawahir Z, Neamati N.,Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. Epub 2006 Aug 1.,,,,,,,,,,,,,,,,,,,,
HIP620,KILEPFRKQNPDIVIYQYMD,20,4286,Reverse Transcriptase,NA,4.8,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP581,ELVNQIIEQLIKKEKVYLAW,20,4321,Reverse Transcriptase,NA,6.9,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP678,PDIVIYQYMDDLYVGSDLEI,20,4287,Reverse Transcriptase,NA,22,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP700,SPAIFQSSMTKILEPFRKQN,20,4285,Reverse Transcriptase,NA,35,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP610,IQAQPDQSESELVNQIIEQL,20,4320,Reverse Transcriptase,NA,>120,μM,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP621,KILEPFRKQNPDIVIYQYMD,20,4286,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP679,PDIVIYQYMDDLYVGSDLEI,20,4287,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP609,IAEIQKQGQGQWTYQIYQEP,20,4302,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP624,KQLTEAVQKITTESIVIWGK,20,4306,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP714,TPKFKLPIQKETWETWWTEY,20,4308,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP727,VVTLTDTTNQKTELQAIYLA,20,4316,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP582,ELVNQIIEQLIKKEKVYLAW,20,4321,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP583,EQVDKLVSAGIRKVLFLDGI,20,4324,Reverse Transcriptase,NA,High,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP568,CTLNFPISPIETVPVKLKPG,20,4269,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP586,ETVPVKLKPGMDGPKVKQWP,20,4270,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP672,MDGPKVKQWPLTEEKIKALV,20,4271,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP671,LTEEKIKALVEICTEMEKEG,20,4272,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP579,EICTEMEKEGKISKIGPENP,20,4273,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP622,KISKIGPENPYNTPVFAIKK,20,4274,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP732,YNTPVFAIKKKDSTKWRKLV,20,4275,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP615,KDSTKWRKLVDFRELNKRTQ,20,4276,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP571,DFWEVQLGIPHPAGLKKKKS,20,4278,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP606,HPAGLKKKKSVTVLDVGDAY,20,4279,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP726,VTVLDVGDAYFSVPLDEDFR,20,4280,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP590,FSVPLDEDFRKYTAFTIPSI,20,4281,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP629,KYTAFTIPSINNETPGIRYQ,20,4282,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP674,NNETPGIRYQYNVLPQGWKG,20,4283,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP733,YNVLPQGWKGSPAIFQSSMT,20,4284,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP576,DLYVGSDLEIGQHRTKIEEL,20,4288,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP601,GQHRTKIEELRQHLLRWGLT,20,4289,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP697,RQHLLRWGLTTPDKKHQKEP,20,4290,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP713,TPDKKHQKEPPFLWMGYELH,20,4291,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP682,PFLWMGYELHPDKWTVQPIV,20,4292,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP680,PDKWTVQPIVLPEKDSWTVN,20,4293,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP666,LPEKDSWTVNDIQKLVGKLN,20,4294,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP573,DIQKLVGKLNWASQIYPGIK,20,4295,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP722,VRQLCKLLRGTKALTEVIPL,20,4297,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP710,TKALTEVIPLTEEAELELAE,20,4298,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP706,TEEAELELAENREILKEPVH,20,4299,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP675,NREILKEPVHGVYYDPSKDL,20,4300,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP604,GVYYDPSKDLIAEIQKQGQG,20,4301,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP690,QWTYQIYQEPFKNLKTGKYA,20,4303,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP695,RMRGAHTNDVKQLTEAVQKI,20,4305,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP715,TTESIVIWGKTPKFKLPIQK,20,4307,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP587,ETWETWWTEYWQATWIPEWE,20,4309,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP731,WYQLEKEPIVGAETFYVDGA,20,4312,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP591,GAETFYVDGAANRETKLGKA,20,4313,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP561,ANRETKLGKAGYVTNRGRQK,20,4314,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP627,KTELQAIYLALQDSGLEVNI,20,4317,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP667,LQDSGLEVNIVTDSQYALGI,20,4318,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP725,VTDSQYALGIIQAQPDQSES,20,4319,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP718,VPAHKGIGGNEQVDKLVSAG,20,4323,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP612,IRKVLFLDGIDKAQDEHEKY,20,4325,Reverse Transcriptase,NA,Low,NA,Integrase,Dot-blot assay,15790559,Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1 as novel inhibitors of the viral integrase.,Oz Gleenberg I, Avidan O, Goldgur Y, Herschhorn A, Hizi A.,J Biol Chem. 2005 Jun 10;280(23):21987-96. Epub 2005 Mar 23.,,,,,,,,,,,,,,,,,
HIP1017,WQCLTLTHRGFVLLTITVLR,20,IN1,Synthetic,HeLa,70,%,Integrase,MAGI Assay,19850483,Peptide inhibitors of HIV-1 integrase: from mechanistic studies to improved lead compounds.,Maes M, Levin A, Hayouka Z, Shalev DE, Loyter A, Friedler A.,Bioorg Med Chem. 2009 Nov 15;17(22):7635-42. Epub 2009 Oct 4.,,,,,,,,,,,,,,,,
HIP1146,WQCLTLTHRGFVLLTITVLR,20,IN-1,Synthetic,HeLa,12,μM,Integrase,ELISA,18201721,Correlation between shiftide activity and HIV-1 integrase inhibition by a peptide selected from a combinatorial library.,Armon-Omer A, Levin A, Hayouka Z, Butz K, Hoppe-Seyler F, Loya S, Hizi A, Friedler A, Loyter A.,J Mol Biol. 2008 Feb 29;376(4):971-82. Epub 2007 Dec 5.,,,,,,,,,,,,,
HIP1140,PDIVIYQYMDDLYVGSDLEI,21,34,pol,NA,6,μM,Integrase,Integrase Assay,16879966,Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome.,Zawahir Z, Neamati N.,Bioorg Med Chem Lett. 2006 Oct 1;16(19):5199-202. Epub 2006 Aug 1.,,,,,,,,,,,,,,,,,,,,
HIP1113,DQAEHLKTAVQMAVFIHNYKA,21,IN 167–187,Integrase,NA,85,nM,Integrase,Integrase Assay,22742518,Peptides that inhibit HIV-1 integrase by blocking its protein-protein interactions.,Maes M, Loyter A, Friedler A.,FEBS J. 2012 Aug;279(16):2795-809. doi: 10.1111/j.1742-4658.2012.08680.x. Epub 2012 Jul 23.,,,,,,,,,,,,,,,,,,,
HIP1139,IHAEIKNSLKIDNLDVNRCIEAL,23,-,LEDGF/p75,NA,25,μM,Integrase,Alpha screen assay,18331842,Inhibitory profile of a LEDGF/p75 peptide against HIV-1 integrase: insight into integrase-DNA complex formation and catalysis.,Al-Mawsawi LQ, Christ F, Dayam R, Debyser Z, Neamati N.,FEBS Lett. 2008 Apr 30;582(10):1425-30. Epub 2008 Mar 10.,,,,,,,,,,,,,,,,,
HIP1051,WIHAEIKNSLKIDNLDVNRCIEALD,25,-,LEDGF/p75,NA,High,NA,Integrase,Integrase Assay,21222490,Dithiothreitol causes HIV-1 integrase dimer dissociation while agents interacting with the integrase dimer interface promote dimer formation.,Tsiang M, Jones GS, Hung M, Samuel D, Novikov N, Mukund S, Brendza KM, Niedziela-Majka A, Jin D, Liu X, Mitchell M, Sakowicz R, Geleziunas R.,Biochemistry. 2011 Mar 15;50(10):1567-81. Epub 2011 Feb 21.,,,,,,,,,
HIP1114,WIHAEIKNSLKIDNLDVNRCIEALD,25,LEDGF-(354–378),LEDGF/p75,NA,2020,nM,Integrase,Integrase Assay,19801648,Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex.,Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R.,J Biol Chem. 2009 Nov 27;284(48):33580-99. Epub 2009 Sep 28.,,,,,,,,
HIP1047,WIHAEIKNSLKIDNLDVNRCIEALD,25,p75 353–378,LEDGF/p75,HeLa,High,NA,Integrase,Gel filtration,17488811,Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium.,Hayouka Z, Rosenbluh J, Levin A, Loya S, Lebendiker M, Veprintsev D, Kotler M, Hizi A, Loyter A, Friedler A.,Proc Natl Acad Sci U S A. 2007 May 15;104(20):8316-21. Epub 2007 May 8.,,,,,,,,,,,,
HIP1054,QRQIRSISGWILSTYLGRPAEPVPLQ,26,Rev49-74 ,rev,TZM-bl,High,NA,Integrase,MAGI Assay,17403681,Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.,Rosenbluh J, Hayouka Z, Loya S, Levin A, Armon-Omer A, Britan E, Hizi A, Kotler M, Friedler A, Loyter A.,J Biol Chem. 2007 May 25;282(21):15743-53. Epub 2007 Apr 2.,,,,,,,,,,,,
HIP971,VESMNKELPKIIGQVRDQAEHLKTAY,26,EAA26,integrase,NA,High,NA,Integrase,Integrase assay,9578482,Helical and coiled-coil-forming properties of peptides derived from and inhibiting human immunodeficiency virus type 1 integrase assessed by 1H-NMR--use of NH temperature coefficients to probe coiled-coil structures.,Krebs D, Maroun RG, Sourgen F, Troalen F, Davoust D, Fermandjian S.,Eur J Biochem. 1998 Apr 1;253(1):236-44.,,,,,,,,,,,,,,,,
HIP1046,VESMNEELKKIIAQVRAQAEHLKTAY,27,EAA26,Integrase,NA,High,NA,Integrase,NMR,10567389,Self-association and domains of interactions of an amphipathic helix peptide inhibitor of HIV-1 integrase assessed by analytical ultracentrifugation and NMR experiments in trifluoroethanol/H(2)O mixtures.,Maroun RG, Krebs D, El Antri S, Deroussent A, Lescot E, Troalen F, Porumb H, Goldberg ME, Fermandjian S.,J Biol Chem. 1999 Nov 26;274(48):34174-85.,,,,,,,,,,,,,
HIP771,SQGVVESMNKELKKIIGQVRDQAEHLKTA,29,K159 ,Synthetic,BL21,High,NA,Integrase,Integrase Assay,10091594,Conformational aspects of HIV-1 integrase inhibition by a peptide derived from the enzyme central domain and by antibodies raised against this peptide.,Maroun RG, Krebs D, Roshani M, Porumb H, Auclair C, Troalen F, Fermandjian S.,Eur J Biochem. 1999 Feb;260(1):145-55.,,,,,,,,,,,,,,,
HIP770,RMIYKNILFYLVPGPGHGAEPERRNIKYL,29,I29,Synthetic,HeLa,85,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP1045,SQGVVESMNKELKKIIGQVRDQAEHLKTAY,30,integrase (147-175),Integrase,NA,High,NA,Integrase,Integrase Assay,8856082,A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Correlated biochemical and spectroscopic results.,Sourgen F, Maroun RG, Frere V, Bouziane M, Auclair C, Troalen F, Fermandjian S.,Eur J Biochem. 1996 Sep 15;240(3):765-73.,,,,,,,,,,,,,,,
HIP1052,MAGRSGDSDEELLKTVRLIKFLYQSNPPPS,30,Rev1-30,rev,TZM-bl,High,NA,Integrase,MAGI Assay,17403681,Interaction between HIV-1 Rev and integrase proteins: a basis for the development of anti-HIV peptides.,Rosenbluh J, Hayouka Z, Loya S, Levin A, Armon-Omer A, Britan E, Hizi A, Kotler M, Friedler A, Loyter A.,J Biol Chem. 2007 May 25;282(21):15743-53. Epub 2007 Apr 2.,,,,,,,,,,,,
HIP969,SQGVVESMNKELKKIIGQVRDQAEHLKTAY,30,K159,Integrase,NA,High,NA,Integrase,Integrase assay,9578482,Helical and coiled-coil-forming properties of peptides derived from and inhibiting human immunodeficiency virus type 1 integrase assessed by 1H-NMR--use of NH temperature coefficients to probe coiled-coil structures.,Krebs D, Maroun RG, Sourgen F, Troalen F, Davoust D, Fermandjian S.,Eur J Biochem. 1998 Apr 1;253(1):236-44.,,,,,,,,,,,,,,,,
HIP970,SQGVVESMNKELPKIIGQVRDQAEHLKTAY,30,P159,Integrase,NA,Low,NA,Integrase,Integrase assay,9578482,Helical and coiled-coil-forming properties of peptides derived from and inhibiting human immunodeficiency virus type 1 integrase assessed by 1H-NMR--use of NH temperature coefficients to probe coiled-coil structures.,Krebs D, Maroun RG, Sourgen F, Troalen F, Davoust D, Fermandjian S.,Eur J Biochem. 1998 Apr 1;253(1):236-44.,,,,,,,,,,,,,,,,
HIP777,QLLIRMIYKNILFYLVPGPGHGAEPERRNIKYL,33,I33,Synthetic,HeLa,9,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP776,LSELDDRADALQAGASQFETSAAKLKRKYWWKN,33,C35,Synthetic,HeLa,>200,μM,Integrase,Disintegration assay,12054767,A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.,de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B.,J Mol Biol. 2002 Apr 19;318(1):45-58.,,,,,,,,,,,,,
HIP980,LLETSEG,7,4/5s,gag,Jurkat,Low,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP991,ATLEEMM,7,28/29s,gag,Jurkat,Medium,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP990,PAATLEEHMTA,11,28/29m,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP979,NPGLLETSEGCRQ,13,4/5m,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP992,AAAPAATLEEHMTACQGV,18,28/29a,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP993,ALGAAATLEEMMTACQGV,18,28/29b,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP997,ALGPAATLEEMMTACAAA,18,28/29f,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP989,ALGPAATLEEMMTACQGV,18,28/29l,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP981,AAANPGLLETSEGCRQIL,18,4/5a,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP978,FAVNPGLLETSEGCRQIL,18,4/5l,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP994,ALGPAAAAAEMMTACQGV,18,28/29c,gag,Jurkat,Low,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP984,FAVNPGLLEAAAGCRQIL,18,4/5d,gag,Jurkat,Low,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP986,FAVNPGLLETSEGCRAAA,18,4/5f,gag,Jurkat,Low,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP996,ALGPAATLEEMMAAAQGV,18,28/29e,gag,Jurkat,Medium,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP985,FAVNPGLLETSEAAAQIL,18,4/5e,gag,Jurkat,Medium,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP1101,GHKARVLAEAMSQVTNPATIM,21,SP1,gag,HeLa,High,NA,Maturation,Single-cycle infectivity assay,20406463,Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.,Adamson CS, Sakalian M, Salzwedel K, Freed EO.,Retrovirology. 2010 Apr 20;7:36.,,,,,,,,,,,,,,,,,,
HIP977,NPGLLETSEGCRQILGQLQPSLQT,24,5,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP987,ANPDCKTILKALGPAATLEEMMTAC,25,28,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP988,AATLEEMMTACQGVGGPGHKARVLA,25,29,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP976,WASRELERFAVNPGLLETSEGCRQIL,26,4,gag,Jurkat,High,NA,Maturation,RT Assay,8207412,Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.,Niedrig M, Gelderblom HR, Pauli G, Marz J, Bickhard H, Wolf H, Modrow S.,J Gen Virol. 1994 Jun;75 ( Pt 6):1469-74.,,,,,,,,,,,,,,,
HIP1041,RRRRRRRRRR,10,R-10,Tat,P4-R5 MAG,0.014,mg/mL,Multifunction,Galactosidase Reporter Gene Assay,22319541,Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,Keogan S, Passic S, Krebs FC.,Int J Pept. 2012;2012:349427. Epub 2012 Jan 29.,,,,,,,,,,,,,,,,,,,
HIP1040,RRKKRRRRRR,10,TPvar3,Tat,P4-R5 MAG,0.025,mg/mL,Multifunction,Galactosidase Reporter Gene Assay,22319541,Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,Keogan S, Passic S, Krebs FC.,Int J Pept. 2012;2012:349427. Epub 2012 Jan 29.,,,,,,,,,,,,,,,,,,,
HIP1038,RRKKRRQRRR,10,TPvar1,Tat,P4-R5 MAG,0.065,mg/mL,Multifunction,Galactosidase Reporter Gene Assay,22319541,Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,Keogan S, Passic S, Krebs FC.,Int J Pept. 2012;2012:349427. Epub 2012 Jan 29.,,,,,,,,,,,,,,,,,,,
HIP1039,GRKKRRRRRR,10,TPvar2,Tat,P4-R5 MAG,0.071,mg/mL,Multifunction,Galactosidase Reporter Gene Assay,22319541,Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,Keogan S, Passic S, Krebs FC.,Int J Pept. 2012;2012:349427. Epub 2012 Jan 29.,,,,,,,,,,,,,,,,,,,
HIP1037,GRKKRRQRRR,10,Tat peptide,Tat,P4-R5 MAG,0.094,mg/mL,Multifunction,Galactosidase Reporter Gene Assay,22319541,Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,Keogan S, Passic S, Krebs FC.,Int J Pept. 2012;2012:349427. Epub 2012 Jan 29.,,,,,,,,,,,,,,,,,,,
HIP185,KRIVQRIKDFLR,12,KR-12,Cathelicidin,CEM-SS,>63.5,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP1065,TYICEVEDQKEE,12,CD4 (81-92),CD4,CEM-SS,High,NA,Multifunction,Syncytia assay,2789382,CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.,Nara PL, Hwang KM, Rausch DM, Lifson JD, Eiden LE.,Proc Natl Acad Sci U S A. 1989 Sep;86(18):7139-43.,,,,,,,,,,,,,,,,,
HIP236,GFLDIIEKIAKSW,13,B7,NA,CEM-SS,10.5,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP244,GWFDIIKKIASEL,13,B4,NA,CEM-SS,10.7,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP239,GIWSDLAEIIKKF,13,B6,NA,CEM-SS,11.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP240,GLFDIIKKIAESW,13,B1,NA,CEM-SS,11.7,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP238,GIIDIAKKLFESW,13,B3,NA,CEM-SS,20.1,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP245,GWLKKIESIIDAF,13,B8,NA,CEM-SS,29.5,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP241,GLWEKIDKFASII,13,B2,NA,CEM-SS,>65.8,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP237,GIFDKLAKEISIW,13,B5,NA,CEM-SS,>65.8,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP235,FKRIVQRIKDFLR,13,FK-13,Cathelicidin,CEM-SS,3.4,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP263,RLFDKIRQVIRKF,13,Retro-FK-1,Cathelicidin,CEM-SS,>58.1,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP268,FLFPLITSFLSKVL,14,Ranatuerin 9 (frog),Ranatuerin 9 (frog),CEM-SS,16.7,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP269,FRPALIVRTKGTRL,14,Hyposin-5 (frog),Hyposin-5 (frog),CEM-SS,>61.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP270,INLKAIAALAKKLL,14,Mastoparan M (insect),Mastoparan M (insect),CEM-SS,>67.6,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP365,VDKPDYRPRPRPPNM,15,Metalnikowin I (insect),Metalnikowin I (insect),CEM-SS,>54.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP297,GRFKRFRKKFKKLFK,15,BMAP-15,Cathelicidin,CEM-SS,>49.6,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP388,GFKRIVQRIKDFLRNLV,17,GF-17,Cathelicidin,CEM-SS,0.98,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP450,GNNRPVYIPQPRPPHPRI,18,Apidaecin IA (insect),Apidaecin IA (insect),CEM-SS,>47.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP452,GRFKRFRKKFKKLFKKIS,18,BMAP-18,Cathelicidin,CEM-SS,0.35,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP453,GRFKRFRKPFKKLFKKIS,18,BMAP-18P9,Cathelicidin,CEM-SS,3.2,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP454,GRFKRIRKKLKKLFKKIS,18,BMAP-18I6L10,Cathelicidin,CEM-SS,>44.0,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP551,GLRRLLGRLLRRLGRLLLR,19,GLR-19,NA,CEM-SS,4.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP549,GKPRPYSPRPTSHPRPIRV,19,Drosocin (insect),Drosocin (insect),CEM-SS,>45.5,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP550,GLKKLLGKLLKKLGKLLLK,19,GLK-19,NA,CEM-SS,>47.5,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP553,KGRGKQGGKVRAKAKTRSS,19,Parasin I (fish),Parasin I (fish),CEM-SS,>50.0,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP703,SWKSMAKKLKEYMEKLKQRA,20,Latarcin 3a (spider),Latarcin 3a (spider),CEM-SS,32.7,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP597,GIKQFKRIVQRIKDFLRNLV,20,GI-20Q16,Cathelicidin,CEM-SS,0.91,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP595,GIKEFKRIVQRIKDFLRNLV,20,GI-20,Cathelicidin,CEM-SS,1.08,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP594,GIKEFKREFQRIKDFLRNLV,20,GI-20EF ,Cathelicidin,CEM-SS,1.6,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP596,GIKEWKRIVQRIKDFLRNLV,20,GI-20W17,Cathelicidin,CEM-SS,7.4,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP625,KRIVQRIKDFLRNLVPRTES,20,KR-20,Cathelicidin,CEM-SS,>40.5,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP737,ILGPVLGLVSRTLRRVLGIL,21,Maximin H5r3,NA,CEM-SS,2.2,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP740,RQRVEELSKFSKKGAAARRRK,21,Misgurin (fish),Misgurin (fish),CEM-SS,>40.0,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP742,TRSSRAGLQFPVGRVHRLLRK,21,Buforin II (toad),Buforin II (toad),CEM-SS,>41.1,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP736,ILGPVLGLVSDTLDDVLGIL,21,Maximin H5,NA,CEM-SS,>49.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP741,SKEKIGKEFKRIVQRIKDFLR,21,SK-21,Cathelicidin,CEM-SS,10.8,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP743,FFHHIFRGIVHVGKTIHRLVTG,22,Piscidin 3 (fish),Piscidin 3 (fish),CEM-SS,2.1,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP749,VFQFLGRIIHHVGNFVHGFSHVF,23,Clavanin B (tunicate),Clavanin B (tunicate),CEM-SS,7.1,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP748,RPKHPIKHQGLPQEVLNENLLRF,23,Isracidin (cow),Isracidin (cow),CEM-SS,>36.2,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP746,LLGDLLRKSKEKIGKEFKRIVQR,23,LL-23,Cathelicidin,CEM-SS,>35.4,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP752,GLRSRIWLWVLLMIWQESNRFKRM,24,DRS S9r3,NA,CEM-SS,1.25,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP753,LLKELWTKIKGAGKAVLGKIKGLL,24,Ponericin L2 (insect),Ponericin L2 (insect),CEM-SS,1.4,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP751,GLRSKIWLWVLLMIWQESNKFKKM,24,DRS S9,NA,CEM-SS,31.6,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP750,GLNTLKKVFQGLHEAIKLINNHVQ,24,Pseudin 1 (frog),Pseudin 1 (frog),CEM-SS,35.7,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP756,HVDKKVADKVLLLKQLRIMRLLTRL,25,Spinigerin (insect),Spinigerin (insect),CEM-SS,3.05,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP758,NLVSGLIEARKYLEQLHRKLKNRKV,25,D88 (frog),D88 (frog),CEM-SS,>33.3,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP755,GAWKNFWSSLRKGFYDGEAGRAIRR,25,D94 (bacteria),D94 (bacteria),CEM-SS,>34.1,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP757,IWLTALKFLGKHAAKHLAKQQLSKL,25,Lycotoxin I (spider),Lycotoxin I (spider),CEM-SS,>35.2,μM,Multifunction,Formazan assay,20086159,Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database.,Wang G, Watson KM, Peterkofsky A, Buckheit RW Jr.,Antimicrob Agents Chemother. 2010 Mar;54(3):1343-6. Epub 2010 Jan 19.,,,,,,,,,,,,,,,,,,
HIP899,LLGDLLRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,LL-37 ,Cathelicidin,CEM-SS,1.6,μM,Multifunction,Cytopathic effect,18591279,Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins.,Wang G, Watson KM, Buckheit RW Jr.,Antimicrob Agents Chemother. 2008 Sep;52(9):3438-40. Epub 2008 Jun 30.,,,,,,,,,,,,,,,,,,,
HIP3,DQ,2,-,gag-pol,NA,>1000,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP2,DE,2,-,gag-pol,NA,5400±380,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP1,DD,2,-,gag-pol,NA,970±140,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP8,YDL,3,-,Synthetic,NA,9,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP9,YEL,3,-,Synthetic,NA,75,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP10,YEW,3,-,Synthetic,NA,88,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP1070,VTN,3,-,gag,NA,Low,NA,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP12,DDL,3,-,gag-pol,NA,140±6,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP4,EKF,3,-,gag-pol,NA,2010±380,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP13,DEL,3,-,gag-pol,NA,230±20,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP14,EDF,3,-,gag-pol,NA,25±3,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP5,ENL,3,-,gag-pol,NA,3070±210,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP16,EEL,3,-,gag-pol,NA,310±25,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP6,RED,3,-,gag-pol,NA,3360±400,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP11,DDF,3,-,gag-pol,NA,43±7,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP15,EDL,3,-,gag-pol,NA,50±9,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP22,SYEW,4,-,Synthetic,NA,75,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP23,SYEY,4,-,Synthetic,NA,75,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP21,SYEL,4,-,Synthetic,NA,80,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP24,SYNL,4,-,Synthetic,NA,440,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP20,SFNL,4,-,Synthetic,NA,900,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP18,DLAF,4,-,gag-pol,NA,270±25,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP19,FDDF,4,-,gag-pol,NA,55±14,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP27,ISYEL,5,-,Synthetic,NA,4.5,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP29,YSYEL,5,-,Synthetic,NA,5.5,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP28,ISYEY,5,-,Synthetic,NA,37,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP25,GEDLA,5,-,gag-pol,NA,160±20,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP1122,LLEYS,5,-,Oyster,NA,120,nM,Protease inhibition,Protease assay,9918775,Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,Lee TG, Maruyama S.,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,,,,,,,,,,,,,,,,,,,,
HIP1077,TVSYD,5,pET3a-21,Recombinant,E.coli,Low,NA,Protease inhibition,Protease assay,9628224,A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.,Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H.,J Virol Methods. 1998 Mar;71(1):77-85.,,,,,,,,,,,,,,,,
HIP85,TISYEL,6,-,Synthetic,NA,6,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP80,IISYEL,6,-,Synthetic,NA,8,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP86,TVSYEL,6,-,Synthetic,NA,12,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP82,LQITLW,6,-,Synthetic,NA,37,μM,Protease inhibition,Enzyme inhibition assay,8783807,The inhibition of human immunodeficiency virus proteases by 'interface peptides'.,Schramm HJ, Boetzel J, Buttner J, Fritsche E, Gohring W, Jaeger E, Konig S, Thumfart O, Wenger T, Nagel NE, Schramm W.,Antiviral Res. 1996 May;30(2-3):155-70.,,,,,,,,,,,
HIP1032,LLEYVF,6,-,Oyster,NA,53,%,Protease inhibition,Protease assay,17981043,Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.,Narendra Babu SN, Rangappa KS.,Bioorg Med Chem. 2008 Jan 15;16(2):874-80. Epub 2007 Oct 22.,,,,,,,,,,,,,,,,,,,
HIP1034,LLEYVY,6,-,Oyster,NA,59,%,Protease inhibition,Protease assay,17981043,Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.,Narendra Babu SN, Rangappa KS.,Bioorg Med Chem. 2008 Jan 15;16(2):874-80. Epub 2007 Oct 22.,,,,,,,,,,,,,,,,,,,
HIP1033,LLEYVM,6,-,Oyster,NA,65,%,Protease inhibition,Protease assay,17981043,Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.,Narendra Babu SN, Rangappa KS.,Bioorg Med Chem. 2008 Jan 15;16(2):874-80. Epub 2007 Oct 22.,,,,,,,,,,,,,,,,,,,
HIP1035,LLEYVW,6,-,Oyster,NA,65,%,Protease inhibition,Protease assay,17981043,Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.,Narendra Babu SN, Rangappa KS.,Bioorg Med Chem. 2008 Jan 15;16(2):874-80. Epub 2007 Oct 22.,,,,,,,,,,,,,,,,,,,
HIP1067,AEAMSQ,6,-,gag,NA,Low,NA,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP33,GEDLAF,6,-,gag-pol,NA,64±13,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP1121,LLEYSL,6,-,Oyster,NA,15,nM,Protease inhibition,Protease assay,9918775,Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,Lee TG, Maruyama S.,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,,,,,,,,,,,,,,,,,,,,
HIP1120,LLEYSI,6,-,Oyster,NA,20,nM,Protease inhibition,Protease assay,9918775,Isolation of HIV-1 protease-inhibiting peptides from thermolysin hydrolysate of oyster proteins.,Lee TG, Maruyama S.,Biochem Biophys Res Commun. 1998 Dec 30;253(3):604-8.,,,,,,,,,,,,,,,,,,,,
HIP1074,TISYDL,6,pET3a-1,Recombinant,E.coli,Low,NA,Protease inhibition,Protease assay,9628224,A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.,Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H.,J Virol Methods. 1998 Mar;71(1):77-85.,,,,,,,,,,,,,,,,
HIP1076,TISYKY,6,pET3a-20,Recombinant,E.coli,Low,NA,Protease inhibition,Protease assay,9628224,A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.,Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H.,J Virol Methods. 1998 Mar;71(1):77-85.,,,,,,,,,,,,,,,,
HIP1078,TITYDY,6,pET3a-22,Recombinant,E.coli,Low,NA,Protease inhibition,Protease assay,9628224,A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.,Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H.,J Virol Methods. 1998 Mar;71(1):77-85.,,,,,,,,,,,,,,,,
HIP1079,TVTYDC,6,pET3a-23,Recombinant,E.coli,Low,NA,Protease inhibition,Protease assay,9628224,A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.,Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H.,J Virol Methods. 1998 Mar;71(1):77-85.,,,,,,,,,,,,,,,,
HIP1075,TVSYEL,6,pET3a-7,Recombinant,E.coli,Low,NA,Protease inhibition,Protease assay,9628224,A rapid and sensitive bacterial assay to determine the inhibitory effect of 'interface' peptides on HIV-1 protease co-expressed in Escherichia coli.,Ast O, Jentsch KD, Schramm HJ, Hunsmann G, Luke W, Petry H.,J Virol Methods. 1998 Mar;71(1):77-85.,,,,,,,,,,,,,,,,
HIP1068,AEAMSQV,7,-,gag,NA,Low,NA,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP1069,AEAMSQVT,8,-,gag,NA,Low,NA,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP1071,VTNTATIM,8,-,gag,NA,Low,NA,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP124,FLRQNLAF,8,-,gag-pol,NA,>2000,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP123,FLREDLAF,8,-,gag-pol,NA,98±10,Ki,Protease inhibition,Enzyme kinetics,9485357,Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.,Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR.,Biochemistry. 1998 Feb 24;37(8):2105-10.,,,,,,,,,,,,,,,,,
HIP135,VHIPLGDA,8,vif 55-62,vif,NA,17,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP126,GWFYRHHY,8,vif 37-44,vif,NA,53.8,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP136,VSIEWRKK,8,vif 85-92,vif,NA,54.6,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP121,EWRKKRYS,8,vif 88-95,vif,NA,60.8,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP130,LGQGVSIE,8,vif 81-88,vif,NA,85,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP125,GKARGWFY,8,vif 33-40,vif,NA,94.8,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP129,IVWQVDRM,8,vif 9-16,vif,NA,Low,NA,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP128,IVWQVDRM,8,Peptide 2,vif,Hut-78,Low,NA,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP1066,AEAMSQVTN,9,-,gag,NA,Medium,NA,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP176,EWRKKRYSTQW,11,vif 88-98,vif,NA,100,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP175,EWRKKRYSTQV,11,Peptide 7,vif,Hut-78,91,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP1152,AEAMSQVTNTATIM,14,p2 gag,gag,NA,10,μM,Protease inhibition,Gel exclusion chromatography,9425262,The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.,Misumi S, Kudo A, Azuma R, Tomonaga M, Furuishi K, Shoji S.,Biochem Biophys Res Commun. 1997 Dec 18;241(2):275-80.,,,,,,,,,,,,,,
HIP310,ISSEVHIPLGDARLV,15,vif 51-65,vif,NA,39.4,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP377,YVSGKARGWFYRHHY,15,vif 30-44,vif,NA,39.6,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP281,DWHLGQGVSIEWRKK,15,vif 78-92,vif,NA,89,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP309,ISSEVHIPLGDARLV,15,Peptide 43,vif,Hut-78,17,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP378,YVSGKARGWFYRHHY,15,Peptide 41,vif,Hut-78,40,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP349,RHHYESPHPRISSEV,15,Peptide 42,vif,Hut-78,40,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP282,DWHLGQGVSIEWRKK,15,Peptide 6,vif,Hut-78,92,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP383,LGDARLVITTYWGLHT,16,vif 58-74,vif,NA,16.6,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP380,ITTYWGLHTGERDWHL,16,vif 66-81,vif,NA,Low,NA,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP381,ITTYWGLHTGERDWHL,16,Peptide 5,vif,Hut-78,90,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP897,YVSGKARGWFYRHHYESPHPRISSEVHIPLGDARLV,36,vif 30-65,vif,NA,75.1,%,Protease inhibition,HPLC,10074409,Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.,Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C.,J Mol Biol. 1999 Mar 19;287(1):93-101.,,,,,,,,,,,,,,,,
HIP896,YVSGKARGWFYRHHYESPHPRISSEVHIPLGDARLV,36,Peptide 4,vif,Hut-78,75,%,Protease inhibition,PR binding assay,9891983,Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.,Baraz L, Friedler A, Blumenzweig I, Nussinuv O, Chen N, Steinitz M, Gilon C, Kotler M.,FEBS Lett. 1998 Dec 28;441(3):419-26.,,,,,,,,,,,,,,
HIP1106,VDGIPVSWDADARAPA,16,152-166,GB virus C,MT-2,High,NA,Replication,MTT assay,18596910,Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.,Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT.,PLoS One. 2008 Jul 2;3(7):e2580.,,,,,,,,,,,,,,,,,
HIP1109,VDGIPVEWDADARAPA,16,S158E,GB virus C,MT-2,High,NA,Replication,MTT assay,18596910,Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.,Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT.,PLoS One. 2008 Jul 2;3(7):e2580.,,,,,,,,,,,,,,,,,
HIP1107,VDGIPVAWDADARAPA,16,S158A,GB virus C,MT-2,Low,NA,Replication,MTT assay,18596910,Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.,Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT.,PLoS One. 2008 Jul 2;3(7):e2580.,,,,,,,,,,,,,,,,,
HIP1108,VDGIPVGWDADARAPA,16,S158G,GB virus C,MT-2,Low,NA,Replication,MTT assay,18596910,Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication.,Xiang J, McLinden JH, Chang Q, Jordan EL, Stapleton JT.,PLoS One. 2008 Jul 2;3(7):e2580.,,,,,,,,,,,,,,,,,
HIP1061,GGAGLTGGFYEPLVRRC,17,E2 276–295,GB virus C gE2,Jurkat,High,NA,Replication,Single cycle replication assay,22608061,Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.,Xiang J, McLinden JH, Kaufman TM, Mohr EL, Bhattarai N, Chang Q, Stapleton JT.,Virology. 2012 Aug 15;430(1):53-62. Epub 2012 May 16.,,,,,,,,,,,,,,,
HIP945,WEEWDKKIEEYTKKIEELIKKSEEQQKN,28,SC29EK,gp41,HeLa CD4,2.4±0.1,nM,Replication,MAGI assay,19114674,SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.,Naito T, Izumi K, Kodama E, Sakagami Y, Kajiwara K, Nishikawa H, Watanabe K, Sarafianos SG, Oishi S, Fujii N, Matsuoka M.,Antimicrob Agents Chemother. 2009 Mar;53(3):1013-8. Epub 2008 Dec 29.,,,,,,,,,
HIP967,KGATYITYVNFLNELRVKTKPEGNSHGIPSLRK,33,K10-K42,GAP31,CEM-T4,High,NA,Replication,ELISA,10195752,Inhibition of human immunodeficiency virus type 1 replication by the K10-K42 peptide of GAP31 is due to induction of rapid but nonspecific precipitation of viral and nonviral proteins.,Fink PD, Alexander IE, Rowe PB, Smythe JA.,AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):429-34.,,,,,,,,,,,,,,,,,,
HIP954,YQCGQGG,7,Ascalin,Shallot bulbs,NA,10,μM,Reverse transcriptase,ELISA,12126728,Ascalin, a new anti-fungal peptide with human immunodeficiency virus type 1 reverse transcriptase-inhibiting activity from shallot bulbs.,Wang HX, Ng TB.,Peptides. 2002 Jun;23(6):1025-9.,,,,,,,,,,,,,,,,,,,
HIP183,GTKWLTEWIPLC,12,P24,Pep-A/Synthetic,HeLa,0.7±0.05,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP182,GTKWLTEVWPLC,12,P16,Pep-A/Synthetic,HeLa,14±4,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP181,GTKAWTEVWPLC,12,P17,Pep-A/Synthetic,HeLa,35±11,(Ki) μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP999,TEYWQATWIPEWE,13,2 (403-415),Reverse transcriptase,MT-4,High,NA,Reverse transcriptase,RT Assay,7513698,Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain.,Divita G, Restle T, Goody RS, Chermann JC, Baillon JG.,J Biol Chem. 1994 May 6;269(18):13080-3.,,,,,,,,,,,,,,,,,
HIP973,TEYWQATWIPEWE,13,P2,Synthetic,NA,High,NA,Reverse transcriptase,RT Assay,7499382,Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors.,Divita G, Baillon JG, Rittinger K, Chermann JC, Goody RS.,J Biol Chem. 1995 Dec 1;270(48):28642-6.,,,,,,,,,,,,,,,,,
HIP259,KWLTEWIPLTAEC,13,P29,Pep-A/Synthetic,HeLa,1±0.4,(Ki) μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP242,GTKAATEVIPLTC,13,P19,Pep-A/Synthetic,HeLa,49±9,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP243,GTKALTEVIPLTC,13,P18,Pep-A/Synthetic,HeLa,53±12,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP276,ASCDKCQLKGEAMHG,15,5649,Integrase,NA,Low,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP314,KCQLKGEAMHGQVDC,15,5650,Integrase,NA,Low,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP332,MHGQVDCSPGIWQLD,15,5652,Integrase,NA,Low,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP337,PGIWQLDCTHLEGKI,15,5654,Integrase,NA,Low,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP364,VDCSPGIWQLDCTHL,15,5653,Integrase,NA,Medium,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP367,VEAIIRILQQLLFIH,15,Vpr 57-71,vpr,NA,0.22,μM,Reverse Transcriptase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP307,IRILQQLLFIHFRIG,15,Vpr 61-75,vpr,NA,0.7,μM,Reverse Transcriptase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP361,TWAGVEAIIRILQQL,15,Vpr 53-67,vpr,NA,0.88,μM,Reverse Transcriptase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP344,QQLLFIHFRIGCQHS,15,Vpr 65-79 ,vpr,NA,33,μM,Reverse Transcriptase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP363,TYGDTWAGVEAIIRI,15,Vpr 49-63 ,vpr,NA,>>150,μM,Reverse Transcriptase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP291,FIHFRIGCQHSRIGI,15,Vpr 69-83,vpr,NA,>>200,μM,Reverse Transcriptase,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP298,GTKWLTEWIPLTAEC,15,P27,Pep-A/Synthetic,HeLa,0.05±0.01,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP323,KWLTEWIPLTAEAEC,15,P26,Pep-A/Synthetic,HeLa,1.8±0.7,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP1000,QKQGQGQWTYQIYQEP,16,3 (330-345),Reverse transcriptase,MT-4,Medium,NA,Reverse transcriptase,RT Assay,7513698,Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain.,Divita G, Restle T, Goody RS, Chermann JC, Baillon JG.,J Biol Chem. 1994 May 6;269(18):13080-3.,,,,,,,,,,,,,,,,,
HIP974,QKQGQGQWTYQIYQEP,16,P3,Synthetic,NA,High,NA,Reverse transcriptase,RT Assay,7499382,Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors.,Divita G, Baillon JG, Rittinger K, Chermann JC, Goody RS.,J Biol Chem. 1995 Dec 1;270(48):28642-6.,,,,,,,,,,,,,,,,,
HIP1001,DVKQLTEAVQKITTESI,17,4 (364-380),Reverse transcriptase,MT-4,Low,NA,Reverse transcriptase,RT Assay,7513698,Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain.,Divita G, Restle T, Goody RS, Chermann JC, Baillon JG.,J Biol Chem. 1994 May 6;269(18):13080-3.,,,,,,,,,,,,,,,,,
HIP975,DVKQLTEAVQKITTESI,17,P4,Synthetic,NA,High,NA,Reverse transcriptase,RT Assay,7499382,Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors.,Divita G, Baillon JG, Rittinger K, Chermann JC, Goody RS.,J Biol Chem. 1995 Dec 1;270(48):28642-6.,,,,,,,,,,,,,,,,,
HIP403,GTKWLTEWIPLTAEAEC,17,PAW,Pep-A/Synthetic,HeLa,0.7± 0.2,(Ki) μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP397,GTKALTEVIPLAEEAEC,17,P13,Pep-A/Synthetic,HeLa,10.2± 2.5,(Ki) μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP386,GAKALTEVIPLTEEAEC,17,P3,Pep-A/Synthetic,HeLa,10.3± 2.1,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP391,GTKALAEVIPLTEEAEC,17,P7,Pep-A/Synthetic,HeLa,13.5±2.1,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP399,GTKALTEVIPLTEAAEC,17,P15,Pep-A/Synthetic,HeLa,14±2.2,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP398,GTKALTEVIPLTAEAEC,17,P14,Pep-A/Synthetic,HeLa,14±3,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP389,GTAALTEVIPLTEEAEC,17,P4,Pep-A/Synthetic,HeLa,15± 2.9,(Ki) μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP393,GTKALTEAIPLTEEAEC,17,P9,Pep-A/Synthetic,HeLa,15±7.3,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP402,GTKWATEWAPLTAEAEC,17,P28,Pep-A/Synthetic,HeLa,2±0.6,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP401,GTKGLTEVIPLTEEAEC,17,P5,Pep-A/Synthetic,HeLa,20±3.7,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP396,GTKALTEVIPATEEAEC,17,P12,Pep-A/Synthetic,HeLa,22±3,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP385,ATKALTEVIPLTEEAEC,17,P2,Pep-A/Synthetic,HeLa,28±11,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP390,GTKAATEVIPLTEEAEC,17,P6,Pep-A/Synthetic,HeLa,5.7±2.3,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP392,GTKALTAVIPLTEEAEC,17,P8,Pep-A/Synthetic,HeLa,57±19,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP387,GAKTETLVIPETELEAC,17,Pscr,Pep-A/Synthetic,HeLa,61± 12,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP395,GTKALTEVIALTEEAEC,17,P11,Pep-A/Synthetic,HeLa,7±1.4,(Ki) μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP394,GTKALTEVAPLTEEAEC,17,P10,Pep-A/Synthetic,HeLa,7.3±2.9,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP400,GTKALTEVIPLTEEAEC,17,P1,Pep-A/Synthetic,HeLa,7.5±2.3,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP518,RGTKALTEVIPLTEEAEC,18,PepA,Pep-A/Synthetic,HeLa,35±5,(Ki)μM,Reverse Transcriptase,RT-Polymerase Assay,18952602,A new generation of peptide-based inhibitors targeting HIV-1 reverse transcriptase conformational flexibility.,Agopian A, Gros E, Aldrian-Herrada G, Bosquet N, Clayette P, Divita G.,J Biol Chem. 2009 Jan 2;284(1):254-64. Epub 2008 Oct 23.,,,,,,,,,,,,,,,,
HIP998,FKLPIQKETWETWWTEYWE,19,1 (389-407),Reverse transcriptase,MT-4,High,NA,Reverse transcriptase,RT Assay,7513698,Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain.,Divita G, Restle T, Goody RS, Chermann JC, Baillon JG.,J Biol Chem. 1994 May 6;269(18):13080-3.,,,,,,,,,,,,,,,,,
HIP972,FKLPIQKETWETWWTEYWE,19,P1,Synthetic,NA,High,NA,Reverse transcriptase,RT Assay,7499382,Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors.,Divita G, Baillon JG, Rittinger K, Chermann JC, Goody RS.,J Biol Chem. 1995 Dec 1;270(48):28642-6.,,,,,,,,,,,,,,,,,
HIP617,KGEAMHGQVDCSPGIWQLDC,20,4330,Integrase,NA,High,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP709,THLEGKVILVAVHVASGYIE,20,4332,Integrase,NA,High,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP602,GRWPVKTIHTDNGSNFTGAT,20,4336,Integrase,NA,Medium,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP616,KELKKIIGQVRDQAEHLKTA,20,4341,Integrase,NA,Medium,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP705,TDIQTKELQKQITKIQNFRV,20,4346,Integrase,NA,Medium,NA,Reverse Transcriptase,Dot-blot binding assay,17257575,Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.,Oz Gleenberg I, Herschhorn A, Goldgur Y, Hizi A.,Arch Biochem Biophys. 2007 Feb 15;458(2):202-12. Epub 2006 Dec 28.,,,,,,,,,,,,,,,,,,
HIP188,QQRRARNGASRS,12,Vpr 85-96,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP331,MEQAPEDQGPQREPY,15,Vpr 1-15,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP286,EPYNEWTLELLEELK,15,Vpr 13-27,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP290,EWTLELLEELKNEAV,15,Vpr 17-31 ,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP285,ELLEELKNEAVRHFP,15,Vpr 21-35 ,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP284,ELKNEAVRHFPRIWL,15,Vpr 25-39,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP283,EAVRHFPRIWLHSLG,15,Vpr 29-43,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP313,IWLHSLGQHIYETYG,15,Vpr 37-51,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP358,SLGQHIYETYGDTWA,15,Vpr 41-55,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP335,PEDQGPQREPYNEWT,15,Vpr 5-19 ,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP352,RIGCQHSRIGITQQR,15,Vpr 73-87,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP341,QHSRIGITQQRRARN,15,Vpr 77-91,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP303,IGITQQRRARNGASR,15,Vpr 81-95,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP296,GPQREPYNEWTLELL,15,Vpr 9-23,vpr,NA,Low,NA,RT/IN,Dot-blot binding assay,17490682,Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr).,Gleenberg IO, Herschhorn A, Hizi A.,J Mol Biol. 2007 Jun 22;369(5):1230-43. Epub 2007 Apr 1.,,,,,,,,,,,,,,,,,,,
HIP1005,RAFVTIGK,8,R8K,gp120,MT-4,66,%,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1009,ELELAENREILK,12,E12K,gp120,MT-4,Low,NA,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1011,STRTPEDSNSLGT,13,S13T,gp120,MT-4,10,%,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1006,TKGPGRVIYATGQ,13,T13Q,gp120,MT-4,75,%,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1007,FEPIPIHYCAFPGF,14,F14F,gp120,MT-4,Low,NA,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1008,KYKLKHIVWASREL,14,K14L,gp120,MT-4,Low,NA,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1002,RIQRGPGRAFVTIGK,15,R15K,gp120,MT-4,100,%,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1010,CTEMEKEGKISKIGP,15,C15P,gp120,MT-4,Low,NA,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1013,DWLKAFYDKVAEKLKEAF,18,18A,Apolipoprotein,HeLa,20,μM,Syncytium formation,Fusion assay,2170446,Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.,Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP.,J Clin Invest. 1990 Oct;86(4):1142-50.,,,,,,,,,,,,,,,,
HIP1014,KWLDAFYKDVAKELEKAF,18,18R,Apolipoprotein,HeLa,>100,μM,Syncytium formation,Fusion assay,2170446,Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.,Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP.,J Clin Invest. 1990 Oct;86(4):1142-50.,,,,,,,,,,,,,,,,
HIP1015,KAFEEVLAKKFYDKALWD,18,18S,Apolipoprotein,HeLa,>100,μM,Syncytium formation,Fusion assay,2170446,Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.,Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP.,J Clin Invest. 1990 Oct;86(4):1142-50.,,,,,,,,,,,,,,,,
HIP1004,NNTRKSIRIQRGPGRAFVTIGKIG,24,N24G,gp120,MT-4,72,%,Syncytium formation,RT Assay,7692087,Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.,Nehete PN, Arlinghaus RB, Sastry KJ.,J Virol. 1993 Nov;67(11):6841-6.,,,,,,,,,,,,,,,,,,,
HIP1175,ITFEDLLDYYGP,12,-,Synthetic,MT-2,4,μM,Virus Assembly,Luciferase assay,18374356,A cell-penetrating helical peptide as a potential HIV-1 inhibitor.,Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK.,J Mol Biol. 2008 May 2;378(3):565-80. Epub 2008 Mar 6.,,,,,,,,,,
HIP1088,ITFEDLLDYYGP,12,CAI,Synthetic,NA,High,NA,Virus Assembly,Electron Microscopy,16041387,A peptide inhibitor of HIV-1 assembly in vitro.,Sticht J, Humbert M, Findlow S, Bodem J, Muller B, Dietrich U, Werner J, Krausslich HG.,Nat Struct Mol Biol. 2005 Aug;12(8):671-7. Epub 2005 Jul 24.,,,,,,,,,,,,,,
HIP1153,FVFLM,5,FM5,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1159,EFVFLM,6,EM6,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1158,PFVFLE,6,PE6,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1160,PEVFLM,6,PEM6,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1157,PFVYLI,6,PI6,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1154,PFVFLM,6,PM6,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1161,PFVFLR,6,PR6,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1155,KPFVFLM,7,KM7,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP1156,NKPFVFLM,8,NM8,alpha1-antitrypsin,NA,>100,μM,Virus entry,Pseudovirus assay,22406118,Short cyclic peptides derived from the C-terminal sequence of &alpha;1-antitrypsin exhibit significant anti-HIV-1 activity.,Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K.,Bioorg Med Chem Lett. 2012 Apr 1;22(7):2393-5. Epub 2012 Feb 22.,,,,,,,,,,,
HIP944,GRKKRRQRRR,10,Tat peptide,Tat,P4-R5 MAG,50,μM,Virus entry,Viral titer,22319541,Infection by CXCR4-Tropic Human Immunodeficiency Virus Type 1 Is Inhibited by the Cationic Cell-Penetrating Peptide Derived from HIV-1 Tat.,Keogan S, Passic S, Krebs FC.,Int J Pept. 2012;2012:349427. Epub 2012 Jan 29.,,,,,,,,,,,,,,,,,,,
HIP177,PRLSHKGPMPF,11,Apelin-11 ,Apelin,NP-2/CD4,Low,NA,Virus entry,Immunofluorescence,10802050,Apelin peptides block the entry of human immunodeficiency virus (HIV).,Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.,FEBS Lett. 2000 May 4;473(1):15-8.,,,,,,,,,,,,,,,,
HIP189,RPRLSHKGPMPF,12,Apelin-12 ,Apelin,NP-2/CD4,63,μg/ml,Virus entry,Immunofluorescence,10802050,Apelin peptides block the entry of human immunodeficiency virus (HIV).,Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.,FEBS Lett. 2000 May 4;473(1):15-8.,,,,,,,,,,,,,,,,
HIP260,QRPRLSHKGPMPF,13,Apelin-13,Apelin,NP-2/CD4,26,μg/ml,Virus entry,Immunofluorescence,10802050,Apelin peptides block the entry of human immunodeficiency virus (HIV).,Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.,FEBS Lett. 2000 May 4;473(1):15-8.,,,,,,,,,,,,,,,,
HIP951,PKSSWSDHEASSGV,14,HA,RhoA,TZM-bl,27,μM,Virus entry,beta galactosidase activity,21198428,A RhoA-derived peptide inhibits human immunodeficiency virus-1 entry in vitro.,Maselko M, Ward C, Pastey M.,Curr HIV Res. 2011 Jan;9(1):1-5.,,,,,,,,,,,,,,,,,,,
HIP405,KFRRQRPRLSHKGPMPF,17,Apelin-17,Apelin,NP-2/CD4,4.8,μg/ml,Virus entry,Immunofluorescence,10802050,Apelin peptides block the entry of human immunodeficiency virus (HIV).,Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.,FEBS Lett. 2000 May 4;473(1):15-8.,,,,,,,,,,,,,,,,
HIP950,TDVILMCFSIDSPDSLENI,19,RhoA77-95,RhoA,TZM-bl,7.8,μM,Virus entry,beta galactosidase activity,21198428,A RhoA-derived peptide inhibits human immunodeficiency virus-1 entry in vitro.,Maselko M, Ward C, Pastey M.,Curr HIV Res. 2011 Jan;9(1):1-5.,,,,,,,,,,,,,,,,,,,
HIP557,AEAIPMSIPPEVKFNKPFVF,20,A1,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP661,LEAIPMSIPPEVKFNKPAVF,20,A18,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP662,LEAIPMSIPPEVKFNKPFAF,20,A19,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP630,LAAIPMSIPPEVKFNKPFVF,20,A2,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP663,LEAIPMSIPPEVKFNKPFVA,20,A20,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP632,LEAAPMSIPPEVKFNKPFVF,20,A4,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP628,KVINPEPIVEPFMSKPFALF,20,Scr,alpha1-antitrypsin,P4-CCR5,>100,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP638,LEAIPCSIPPCVAFNKPFVF,20,A13,C6,11,alpha1-antitrypsin,P4-CCR5,0.18±0.08,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP635,LEAIPCSIPPCFAFNKPFVF,20,A13,C6,11F12,alpha1-antitrypsin,P4-CCR5,0.27±0.04,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP639,LEAIPCSIPPCVFFGKPFVF,20,C6,11,F13,G15,alpha1-antitrypsin,P4-CCR5,0.28±0.02,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,
HIP637,LEAIPCSIPPCFLFGKPFVF,20,C6,11,F12,L13,G15,alpha1-antitrypsin,P4-CCR5,0.39±0.13,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,
HIP656,LEAIPMSIPPEVFFNKPFVF,20,F13,alpha1-antitrypsin,P4-CCR5,0.66±0.06,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP642,LEAIPCSIPPCVGFGKPFVF,20,C6,11,G13,15,alpha1-antitrypsin,P4-CCR5,0.73±0.13,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,
HIP643,LEAIPCSIPPCVLFNKPFVF,20,C6,11,L13,alpha1-antitrypsin,P4-CCR5,0.84±0.08,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP640,LEAIPCSIPPCVFFNKPFVF,20,C6,11,F13,alpha1-antitrypsin,P4-CCR5,0.93±0.05,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP646,LEAIPMCIPPECAFNKPFVF,20,A13,C7,12,alpha1-antitrypsin,P4-CCR5,1.00±0.21,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP652,LEAIPMSIPPEFLFGKPFVF,20,F12,L13,G15,alpha1-antitrypsin,P4-CCR5,1.34±0.42,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP651,LEAIPMSIPPEAKFNKPFVF,20,A12,alpha1-antitrypsin,P4-CCR5,10.64±2.23,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP659,LEAIPMSIPPEVKFNAPFVF,20,A16,alpha1-antitrypsin,P4-CCR5,10.81±0.68,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP650,LEAIPMSIPPAVKFNKPFVF,20,A11,alpha1-antitrypsin,P4-CCR5,11.00±4.75,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP660,LEAIPMSIPPEVKFNKAFVF,20,A17,alpha1-antitrypsin,P4-CCR5,12.72±10.17,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP634,LEAIPASIPPEVKFNKPFVF,20,A6,alpha1-antitrypsin,P4-CCR5,13.00±1.04,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP664,LEAIPMSIPPEVKFNKPFVF,20,VIRIP,alpha1-antitrypsin,P4-CCR5,14.79±2.56,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP648,LEAIPMSIAPEVKFNKPFVF,20,A9,alpha1-antitrypsin,P4-CCR5,16.33±4.34,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP658,LEAIPMSIPPEVKFAKPFVF,20,A15,alpha1-antitrypsin,P4-CCR5,17.41±3.66,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP647,LEAIPMSAPPEVKFNKPFVF,20,A8,alpha1-antitrypsin,P4-CCR5,23.46±0.28,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP633,LEAIAMSIPPEVKFNKPFVF,20,A5,alpha1-antitrypsin,P4-CCR5,23.50±5.19,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP654,LEAIPMSIPPEVAFAKPFVF,20,A13,15,alpha1-antitrypsin,P4-CCR5,3.45±0.44,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,
HIP657,LEAIPMSIPPEVKANKPFVF,20,A14,alpha1-antitrypsin,P4-CCR5,4.62±1.32,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP655,LEAIPMSIPPEVAFNKPFVF,20,A13,alpha1-antitrypsin,P4-CCR5,4.73±0.61,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP649,LEAIPMSIPAEVKFNKPFVF,20,A10,alpha1-antitrypsin,P4-CCR5,9.72±1.66,μM,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,,
HIP636,LEAIPCSIPPCFAFNKPFVF,20,A13,C6,11F12,alpha1-antitrypsin,P4-CCR5,High,NA,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,
HIP645,LEAIPCSIPPEFLFGKPFVF,20,C6,P12,alpha1-antitrypsin,P4-CCR5,High,NA,Virus entry,ELISA,17448989,Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.,Munch J, Standker L, Adermann K, Schulz A, Schindler M, Chinnadurai R, Pohlmann S, Chaipan C, Biet T, Peters T, Meyer B, Wilhelm D, Lu H, Jing W, Jiang S, Forssmann WG, Kirchhoff F.,Cell. 2007 Apr 20;129(2):263-75.,,,,
HIP947,GCKKYRRFRWKFKGKFWFWG,20,pep 19-2.5,Synthetic,TZM-bl,2.9,μM,Virus entry,Luciferase assay,22457281,A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses.,Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U.,J Infect Dis. 2012 Jun;205(11):1654-64. Epub 2012 Mar 28.,,,,,,,,,,
HIP948,GKKYRRFRWKFKFGKWFWFG,20,pep 19-4,Synthetic,TZM-bl,8,μM,Virus entry,Luciferase assay,22457281,A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses.,Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U.,J Infect Dis. 2012 Jun;205(11):1654-64. Epub 2012 Mar 28.,,,,,,,,,,
HIP686,PTGERVWDRGNVTLLCDCPN,20,P4,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP694,RIPTGERVWDRGNVTLLCDC,20,P4-4,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP728,WDRGNVTLLCDCPNGPWVWV,20,P4-7,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP600,GPWVWVPAFCQAVGWGDPIT,20,P6,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP712,TLLCDCPNGPWVWVPAFCQA,20,P6-1,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP631,LCDCPNGPWVWVPAFCQAVG,20,P6-2,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP569,DCPNGPWVWVPAFCQAVGWG,20,P6-3,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP684,PNGPWVWVPAFCQAVGWGDP,20,P6-4,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP730,WVWVPAFCQAVGWGDPITHW,20,P6-5,GB virus C gE2,TZM-bl,High,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP592,GAPASVLGSRPFDYGLKWQS,20,P1,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP724,VSVTCVWGSVSWFASTGGRD,20,P10,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP702,SWFASTGGRDSKIDVWSLVP,20,P11,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP699,SKIDVWSLVPVGSASCTIAA,20,P12,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP717,VGSASCTIAALGSSDRDTVV,20,P13,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP665,LGSSDRDTVVELSEWGVPCV,20,P14,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP580,ELSEWGVPCVTCILDRRPAS,20,P15,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP704,TCILDRRPASCGTCVRDCWP,20,P16,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP563,CGTCVRDCWPETGSVRFPFH,20,P17,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP585,ETGSVRFPFHRCGTGPRLTK,20,P18,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP691,RCGTGPRLTKDLEAVPFVNR,20,P19,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP681,PFDYGLKWQSCSCRANGSRI,20,P2,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP575,DLEAVPFVNRTTPFTIRGPL,20,P20,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP716,TTPFTIRGPLGNQGRGNPVR,20,P21,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP599,GNQGRGNPVRSPLGFGSYTM,20,P22,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP701,SPLGFGSYTMTKIRDSLHLV,20,P23,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP711,TKIRDSLHLVKCPTPAIEPP,20,P24,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP614,KCPTPAIEPPTGTFGFFPGV,20,P25,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP708,TGTFGFFPGVPPINNCMPLG,20,P26,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP685,PPINNCMPLGTEVSEALGGA,20,P27,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP707,TEVSEALGGAGLTGGFYEPL,20,P28,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP598,GLTGGFYEPLVRRCSELMGR,20,P29,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP566,CSCRANGSRIPTGERVWDRG,20,P3,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP723,VRRCSELMGRRNPVCPGYAW,20,P30,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP696,RNPVCPGYAWLSSGRPDGFI,20,P31,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP669,LSSGRPDGFIHVQGHLQEVD,20,P32,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP565,CRANGSRIPTGERVWDRGNV,20,P4-1,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP560,ANGSRIPTGERVWDRGNVTL,20,P4-2,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP603,GSRIPTGERVWDRGNVTLLC,20,P4-3,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP593,GERVWDRGNVTLLCDCPNGP,20,P4-5,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP698,RVWDRGNVTLLCDCPNGPWV,20,P4-6,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP676,NVTLLCDCPNGPWVWVPAFC,20,P5,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP729,WVPAFCQAVGWGDPITHWSH,20,P6-6,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP677,PAFCQAVGWGDPITHWSHGQ,20,P6-7,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP588,FCQAVGWGDPITHWSHGQNQ,20,P6-8,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP687,QAVGWGDPITHWSHGQNQWP,20,P7,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP608,HWSHGQNQWPLSCPQYVYGS,20,P8,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP668,LSCPQYVYGSVSVTCVWGSV,20,P9,GB virus C gE2,TZM-bl,Low,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP693,RGNVTLLCDCPNGPWVWVPA,20,P4-8,GB virus C gE2,TZM-bl,Medium,NA,Virus entry,Luciferase assay,21543477,Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.,Koedel Y, Eissmann K, Wend H, Fleckenstein B, Reil H.,J Virol. 2011 Jul;85(14):7037-47. Epub 2011 May 4.,,,,,,,,,,,,,,,,,
HIP946,PKDGPSPGGTLMDLSERQEVSSVRSLSST,29,DLC1,Dynein,HeLa,High,NA,Virus entry,MAGI assay,17919453,Dynein light chain 1 peptide inhibits human immunodeficiency virus infection in eukaryotic cells.,Fontenot DR, den Hollander P, Vela EM, Newman R, Sastry JK, Kumar R.,Biochem Biophys Res Commun. 2007 Nov 30;363(4):901-7. Epub 2007 Sep 21.,,,,,,,,,,,,,,,,
HIP824,LVQPRGPRSGPGPWQGGRRKFRRQRPRLSHKGPMPF,36,Apelin-36,Apelin,NP-2/CD4,0.3,μg/ml,Virus entry,Immunofluorescence,10802050,Apelin peptides block the entry of human immunodeficiency virus (HIV).,Zou MX, Liu HY, Haraguchi Y, Soda Y, Tatemoto K, Hoshino H.,FEBS Lett. 2000 May 4;473(1):15-8.,,,,,,,,,,,,,,,,
HIP963,CTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHC,36,CTR36,gp120,JY,Low,NA,Virus entry,MTT assay,9811711,T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.,Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T.,J Virol. 1998 Dec;72(12):9763-70.,,,,,,,,,,,,,,
HIP958,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,T20,gp41,PM-1,95,%,Virus entry,Flow cytometry,11222732,Membrane-anchored peptide inhibits human immunodeficiency virus entry.,Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, Stiegler G, Welker R, von Laer D.,J Virol. 2001 Mar;75(6):3038-42.,,,,,,,,,,,,,
HIP959,YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA,36,T20,gp41,PM-1,95,%,Virus entry,Flow cytometry,11222732,Membrane-anchored peptide inhibits human immunodeficiency virus entry.,Hildinger M, Dittmar MT, Schult-Dietrich P, Fehse B, Schnierle BS, Thaler S, Stiegler G, Welker R, von Laer D.,J Virol. 2001 Mar;75(6):3038-42.,,,,,,,,,,,,,
HIP965,EINCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHCNIS,41,V3-ADA,gp120,JY,Low,NA,Virus entry,MTT assay,9811711,T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.,Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T.,J Virol. 1998 Dec;72(12):9763-70.,,,,,,,,,,,,,,
HIP962,EINCTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHCNIS,42,V3-BH10,gp120,JY,High,NA,Virus entry,MTT assay,9811711,T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.,Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T.,J Virol. 1998 Dec;72(12):9763-70.,,,,,,,,,,,,,,
HIP964,ESVKITCARPYQNTRQRTPIGLGQSLYTTRSRSIIGQAHCNIS,43,V3-ELI,gp120,JY,High,NA,Virus entry,MTT assay,9811711,T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.,Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T.,J Virol. 1998 Dec;72(12):9763-70.,,,,,,,,,,,,,,
HIP966,ESVVINCTRPNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNIS,44,V3-89.6,gp120,JY,High,NA,Virus entry,MTT assay,9811711,T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.,Sakaida H, Hori T, Yonezawa A, Sato A, Isaka Y, Yoshie O, Hattori T, Uchiyama T.,J Virol. 1998 Dec;72(12):9763-70.,,,,,,,,,,,,,,
HIP1016,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFRS,48,-,gp41,PM-1,High,NA,Virus entry,Flow cytometry,18449216,Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.,Zahn RC, Hermann FG, Kim EY, Rett MD, Wolinsky SM, Johnson RP, Villinger F, von Laer D, Schmitz JE.,Gene Ther. 2008 Sep;15(17):1210-22. Epub 2008 May 1.,,,,,,,,,,,,,
HIP953,WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFRS,48,C46,gp41,PM-1,High,NA,Virus entry,Fusion kinetics,14694088,Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.,Egelhofer M, Brandenburg G, Martinius H, Schult-Dietrich P, Melikyan G, Kunert R, Baum C, Choi I, Alexandrov A, von Laer D.,J Virol. 2004 Jan;78(2):568-75.,,,,,,,,,,,,
HIP1169,IYWNVSGW,8,-,Synthetic,293T,7,μM,Virus release,Reverse two-hybrid system,19099395,Peptide inhibitors of HIV-1 egress.,Waheed AA, Freed EO.,ACS Chem Biol. 2008 Dec 19;3(12):745-7.,,,,,,,,,,,,,,,,,,,,
HIP1104,TNWYGSGW,8,-,Synthetic,293T,High,NA,Virus release,Reverse two-hybrid system,19099395,Peptide inhibitors of HIV-1 egress.,Waheed AA, Freed EO.,ACS Chem Biol. 2008 Dec 19;3(12):745-7.,,,,,,,,,,,,,,,,,,,,
HIP1105,TLLVYSGW,8,-,Synthetic,293T,High,NA,Virus release,Reverse two-hybrid system,19099395,Peptide inhibitors of HIV-1 egress.,Waheed AA, Freed EO.,ACS Chem Biol. 2008 Dec 19;3(12):745-7.,,,,,,,,,,,,,,,,,,,,
HIP253,KGLSGPSEWWVWV,13,P18,Synthetic,HP16,High,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP256,KGLSGPTAWWVVV,13,P9,Synthetic,HP16,High,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP254,KGLSGPSIRWWLV,13,P1,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP249,KGLSGPFFWWLFV,13,P10,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP258,KGLSGPWCRWWLV,13,P11,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP252,KGLSGPRYVWWLV,13,P12,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP250,KGLSGPGGWWGFV,13,P13,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP255,KGLSGPSWWLFCV,13,P16,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP247,KGLSGPESRWWVV,13,P2,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP248,KGLSGPFCSWWWV,13,P3,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP257,KGLSGPTVQWWVV,13,P5,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP246,KGLSGPAVPWWVV,13,P6,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP251,KGLSGPQGSWWVV,13,P7,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
HIP472,KGLSGPCGWWVWSRGSGK,18,P4,Synthetic,HP16,Medium,NA,vpr,Yeast growth arrest,12379652,Genetic selection of peptide inhibitors of human immunodeficiency virus type 1 Vpr.,Yao XJ, Lemay J, Rougeau N, Clement M, Kurtz S, Belhumeur P, Cohen EA.,J Biol Chem. 2002 Dec 13;277(50):48816-26. Epub 2002 Oct 11.,,,,,,,,,,,,,,,
